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11 Introduction
1.1 Structure-based drug design
The genome sequencing projects provide us with an increasing number of fully assigned
genomes, including those of humans and vertebrates (e.g. mouse) and important mi-
crobial pathogens [Marcotte et al., 1999; Broder & Venter, 2000; Lander et al., 2001;
Rubin et al., 2000]. The total number of protein sequences in the Swiss-Prot database
[Boeckmann et al., 2003] is about 122600 as of February 2003. In contrast, the number
of protein structures deposited in the PDB is 21248 for the same date. Although the
rate of experimental structure determination will continue to increase, the number of
newly discovered sequences grows much faster than the number of structures solved
(Fig. 1.1).
As a matter of fact, the number of experimentally determined novel protein folds has
steadily decreased over the last years (see Fig. 1.2). Actually, 90 % of the protein
structures solved today correspond to already known folds (Fig. 1.2).
Structural genomics is expected to yield a large number of experimentally determined
protein structures, in the long run hopefully resulting in a complete coverage of protein
folding space [Sanchez et al., 2000; Brenner, 2000; Brenner & Levitt, 2000; Holm &
Sander, 1996]. Thus, referring to suitable reference structures, well spread in sequence
and folding space, it will become increasingly possible to generate realistic models
for any given protein sequence using comparative modelling techniques [Marti-Renom
et al., 2000]. This technique can be considered sufficiently mature, given that there has
been only a marginal improvement in the comparative modelling results while going
from CASP3 to CASP4 [Tramontano et al., 2001]. Its rate of success depends on the
degree of sequence identity with the template structure (as a rule of thumb at least 30
%) and the reliability of the underlying sequence alignment [Moult et al., 1999; Venclo-
vas et al., 2001]. As an advantage, the regions predicted best are often the biologically
important ones, [Wei et al., 1999], because they are structurally most conserved by
evolution. This provides the perspective that structural genomics will support biology
and medicine through the annotation of protein function [Thornton et al., 1999, 2000;
Skolnick et al., 2000; Andrade et al., 1999]. Furthermore, the generated protein struc-
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Figure 1.1: Sequence - Structure gap. The number of protein sequences in
SWISS-PROT and protein structures in the PDB are plotted as annual dis-
tribution. Data from http://us.expasy.org/sprot/relnotes/index.html and
http://pdb.protein.osaka-u.ac.jp/pdb/holdings table.html.
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tural models can be used for virtual screening to discover potential new lead structures
for drug therapy [Russell & Eggleston, 2000].
For the rational structure-based design of drugs, knowledge of the three-dimensional
structure of the target protein is indeed inevitably required. The approach followed
here starts from a known or hypothetical binding mechanism. A lead structure is
rationally designed and subsequently tested experimentally. The obtained results are
fed back into a design cycle as new information.
However, if the structure of a target protein is not available, currently two distinct
concepts are followed to discover novel drugs. On the one hand side, it is possible
to establish a 3D QSAR (quantitative structure-activity relationship) model on the
basis of a set of known ligands to extract 3D features primarily explaining observed
trends in binding affinity. On the other hand, a homology model of the target protein
can be constructed and subsequently used for the search of novel ligands, e.g. by
virtual screening. While the QSAR approach is solely based on features derived from
the ligands, the second approach only considers information available from the related
proteins. The latter procedure is in fact rather approximate, especially if in the query
Figure 1.2: The number of protein structures solved versus the identification of
new folds. In blue the number of novel folds is given, in red the number of newly
solved structures. From http://www.rcsb.org/pdb/holdings.html.
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protein several amino acids in the active site are replaced with respect to the references.
Although ligands binding to a particular protein provide implicit information about
the complementary features required at the protein active site, to the best of our
knowledge, there is so far no approach which considers ligand information explicitly
already during the comparative modelling step.
Figure 1.3: Targets of currently marketed small-molecule drugs, subdivided by
biochemical class. Data from [Hopkins & Groon, 2002].
Fig. 1.3 gives an overview over currently launched drugs with respect to the addressed
targets grouped into several biochemical classes. Enzymes represent nearly half of the
total drug targets (47 %), whereas G-protein coupled receptors account for 30 %. Con-
sidering that for none of the G-protein coupled receptors (except for bovine rhodopsin)
the 3D-structure is experimentally determined and that for most ion channels and a
considerable amount of the enzymes the 3D-structure is not available, it becomes obvi-
ous that drug design is indeed frequently faced with the situation that a ligand has to
be discovered for a target protein for which no experimentally determined structure is
yet available. A recent estimate about the number of expected new molecular targets
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in the post-genomic era indicates that this overall distribution will virtually remain
[Hopkins & Groon, 2002].
Thus, to take advantage of the principles of structure-based drug design, methods are
required which generate (more) realistic models of protein binding sites.
1.2 Scope of this thesis
The present work describes in detail how data about related proteins can be comple-
mented with information about the binding modes of bioactive ligands to generate
more realistic homology models of protein binding-sites. As a prerequisite for this ap-
proach, it is assumed that (1) information about ligands binding to the target protein
is available and (2) that the 3D structures of related proteins with significant sequence
identity are known.
Figure 1.4 provides a schematic overview of the strategy. It was initiated by the devel-
opment of the DragHome concept [Schafferhans & Klebe, 2001] and is followed by the
MOBILE approach (Modelling Binding Sites Including Ligand Information Explicitly).
Starting with the (crystal) structure of one or more template proteins, several pre-
liminary homology models of the target protein are generated (step 1). After placing
one or more ligands, known to bind to the target protein, into an averaged binding-
site representation of the generated binding-site models (step 2), new protein models
are generated, now considering explicitly the docked ligand(s) (step 3). After scoring
the thus generated complexes with DrugScore, a final model is obtained by selecting
the model which explains best the observed ligand binding (affinities). The modelled
complexes can be further refined considering a composite picture of the best side-chain
conformers taken from different models and minimising the side-chain-to-ligand inter-
actions using a common force-field (step 4).
In chapter 4 of this work, the presented MOBILE approach is applied to a relevant
real-life test example. Based on the crystal structure of bovine rhodopsin a homology
model of the neurokinin-1 receptor, a G-protein coupled receptor, is generated, under
explicit consideration of known antagonists. This model is then successfully used for
the search of new neurokinin-1 antagonists.
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Figure 1.4: Schematic overview over the approach presented in this thesis: After
generating preliminary models of the target protein (1), the ligand is docked into the
superimposed ensemble of homology models (2). In the next step (3), new homology
models of the target protein are generated under explicit consideration of the ligand
in its docked orientation. Finally (4), the modelled complexes are further optimised
by combining fragments from different models and subjecting the entire complex to an
energy minimisation
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As outlined in the introduction, the approach presented in this Thesis consists of meth-
ods related to the prediction and evaluation of protein structures and protein-ligand
complexes. These issues are covered by homology modelling, docking and scoring. Fur-
ther relevant issues essential for the understanding of the presented approach are the
problem of protein flexibility (especially in the active site), strategies for ligand-based
drug design (i.e. 3D-QSAR approaches) and methods which combine protein- and
ligand-based approaches. This chapter gives a brief summary of currently available
approaches and applications. A detailed description will be given for those methods
which have actually been used in the context of this work.
2.1 Prediction of protein structure
A prerequisite for the understanding of protein-ligand interactions at the atomic level
is the knowledge of the 3D structure of the target protein. Experimental 3D struc-
tures of proteins at atomic resolution are obtained by X-ray crystallography [Glusker
et al., 1994; Drenth, 1999] and NMR [Wu¨thrich, 1986; Siegal et al., 1999; Clore & Gro-
nenborn, 1991]. In these techniques, a model of the protein is constructed such that
consistency with the experimental diffraction or NOE data is achieved. However, the
rate at which protein sequences are determined exceeds far the rate at which protein
structures are solved experimentally. Furthermore, many pharmacologically important
targets are membrane-bound proteins, such as G-protein-coupled receptors (GPCRs),
ion channels, or transporter proteins, for which the experimental determination of the
3D structure is, due to technical difficulties, either still impossible or can only be re-
alised with immense experimental effort and complexity.
If the structure of a protein is not given, a theoretical approach for prediction of
the structure based on the proteins sequence is required. This section provides a
brief overview over the principles of protein structures and outlines strategies for their
modelling and validation. A comprehensive introduction will be given for the program
MODELLER, which has been used in this study for the generation of homology models.
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2.1.1 Basic principles of protein structure
Proteins are polymers composed by the sequences based on twenty different amino acids
which are connected by amide bonds. Although adopting unregular tertiary structures,
common secondary and supersecondary structure motifs frequently occur in proteins.
The most common motifs are the α-helix and the β-strand. These secondary structural
elements are connected by loops which adopt less regular structures, such as β-turns
[Wilmot & Thornton, 1988].
It has been demonstrated that the native tertiary structure of a given protein is de-
termined solely by the protein’s amino acid sequence [Anfinsen, 1973]. The native
structure corresponds to the global minimum of free energy in the protein-solvent sys-
tem (thermodynamic hypothesis). Levinthal showed that folding cannot be simulated
or screened via a systematical search of all possible conformations because it would take
”longer than the lifetime of a universe” [Levinthal, 1968]. The protein folding process
has been investigated by Monte Carlo (MC) simulations on a 27-bead self-avoiding
chain on a cubic lattice [Sali et al., 1994a,b; Dinner et al., 1996]. From these studies a
three-stage process was suggested: Folding starts by a rapid (∼ 104 MC steps) collapse
from a random-coil state to a random semi-compact globule. It then proceeds by a
slow, rate-determining search (∼ 107 MC steps) through the (∼ 1010) semi-compact
states to find one of about 1000 similar transition states from which the chain rapidly
(∼ 105 MC steps) folds to the native state.
The surface of water-soluble globular proteins preferentially consists of polar and
charged amino acids while the interior is composed almost entirely of hydrophobic
amino acids. The packing of these residues, which is almost perfect [Klapper, 1971;
Tsai et al., 1999], is a consequence of the hydrophobic effect [Kauzmann, 1959], which
is generally assumed to be of entropic origin. Water molecules around a non-polar
solute form a cage-like (”iceberg”) structure, which locally reduces the entropy [Frank
& Evans, 1945]. When the non-polar residues of the unfolded protein associate, the
water molecules are liberated, increasing the entropy, which is the dominating part of
the overall free energy of folding [Tsai & Levitt, 1997].
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2.1.2 Approaches for predicting protein structure
Protein structure prediction is divided into two basic areas, depending on the existence
and similarity of homologous template proteins to the given target protein sequence:
• ab initio methods
• homology/comparative modelling techniques
However, the dividing line between these two approaches is diminishing and they are,
to some extent, complementary to each other. Principally, threading methods [Bowie
et al., 1991; Jones et al., 1992; Jones & Thornton, 1993], which cooperatively fit se-
quences onto known three-dimensional folds, could be considered as a combination of
the two because threading samples sequences to known protein conformations in the
PDB and evaluates them in terms of physical energies.
Progress in protein structure prediction methods is assessed by the Critical Assessment
of Protein Structure Prediction (CASP) meetings [Moult et al., 1995, 1997, 1999, 2001].
In CASP, sequences of proteins whose experimental structures are soon to be released
are made publically available. Computational research groups are then invited to
predict 3D structures starting with the target sequence and any other publicly available
information.
ab initio protein folding
Based on Anfinsen’s afore-mentioned thermodynamic hypothesis it should be theoreti-
cally possible to calculate the 3D structure of a protein from its amino acid sequence
by exact description of the physical environment within the cell and computing the
molecular dynamics based on the underlying physical laws [van Gunsteren, 1998; Duan
& Kollman, 1998].
Ab initio prediction methods require three elements: a representation of the protein
geometry, a force field, and an energy surface searching technique [Osguthorpe, 2000].
Almost all methods use some kind of simplified geometry model, in which single vir-
tual atoms represent a number of atoms in the all-atom model. The phase space to
be searched is either continuous (off-lattice models, e.g. [Liwo et al., 1997a,b, 1998;
Osguthorpe, 1997, 1999]) or discrete (lattice models, see [Godzik et al., 1993; Skolnick
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et al., 1997; Ortiz et al., 1998; Hinds & Levitt, 1992]). The potential functions are usu-
ally statistical potentials which are either derived from knowledge-based approaches
[Hinds & Levitt, 1994; Samudrala & Moult, 1998] or use an underlying physical model
parameterised at experimental data [Liwo et al., 1997a,b, 1998; Pillardy et al., 2001;
Hao & Scheraga, 1999; Osguthorpe, 1997, 1999]. Standard search techniques such as
genetic algorithms, Monte Carlo and simulated annealing are usually applied to explore
the conformational space of proteins.
Compared to results from earlier CASP experiments, in CASP4 longer fragments (of
up to 124 residues) of proteins were predicted within 6 A˚ deviation from the crystal
structure.
The resolution of current ab initio structure prediction techniques may be sufficient for
genome annotation; however, it is clearly not yet precise enough for detailed studies
such as docking and drug design [Hardin et al., 2002].
Homology modelling
The most reliable technique for predicting protein structures is homology modelling,
provided the geometry of one or more template proteins with sufficient sequence iden-
tity are given. If the sequence identity between template and target protein is high
enough, the resulting model may even be sufficiently accurate to perform structure-
based drug design.
In homology modelling, one or more template proteins with high sequence identity
to the target sequence are identified. The target and template sequences are aligned,
and a three-dimensional structure of the target protein is generated starting with the
coordinates of the aligned residues of the template protein, combined with models for
loop regions and other unaligned segments. The assembled 3D-model is then refined
to bring it closer to the structure of the target protein.
Major difference between the various homology modelling techniques is how the 3D
model is calculated from the sequence alignment [Sali, 1995b,a]. The original homology
method is based on rigid-body assembly [Browne et al., 1969; Greer, 1981; Blundell et al.,
1987]. The model is constructed from several core regions and from loops and side-
chains, which are taken from related structures. The assembly involves fitting rigid
bodies onto the framework, which is defined as the average of the Cα atoms in the
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conserved folding regions. A further group of methods, modelling by segment matching,
uses approximate positions of conserved atoms from the template protein structures
to calculate the coordinates of the remaining atoms [Jones & Thirup, 1986; Unger
et al., 1989; Claessens et al., 1989; Levitt, 1992]. This is achieved using a database of
short segments of protein structure, energy or geometry rules, or a combination of these
criteria. The third group of methods, modelling by satisfaction of spatial restraints, uses
either distance geometry [Havel & Snow, 1991; Srinivasan et al., 1993] or optimisation
techniques [Sali & Blundell, 1993] to satisfy spatial restraints defined by the alignment
of the target sequence to homologous template protein structures. In addition to the
methods for modelling the entire fold, numerous other techniques for predicting loops
[Fideslis et al., 1994; Lessel & Schomburg, 1999] and side-chains [Vasquez, 1996] with
respect to a given backbone have also been described. These methods are often used
in combination with each other.
The performance of the top eight comparative modelling groups at CASP4 was roughly
similar [Tramontano et al., 2001; Marti-Renom et al., 2002]. The key element for
successful model building is the quality of the sequence alignment, in particular in
regions of low sequence identity. There is a limit for the alignment accuracy that can
be achieved for distantly related proteins because their residual sequence similarity that
guides the alignment becomes weaker with greater evolutionary distance [Schonbrun
et al., 2002].
The accuracy of a comparative model is related to the percentage sequence identity on
which it is based, it is thus correlated with the relationship between the structural and
sequence similarity of two proteins (Fig. 2.1) [Marti-Renom et al., 2000; Sanchez &
Sali, 1998; Koehl & Levitt, 1999]. Models based on more than 50 % sequence identity
with their templates tend to have not more than 1 A˚ rms deviation with respect to
the main-chain atoms. Medium-accuracy comparative models are based on 30 to 50 %
sequence identity. They tend to have about 90 % of the main-chain modelled with 1.5
A˚ rms error.[Baker & Sali, 2001] As an advantage, the regions predicted best are often
the biologically important ones [Bates et al., 2001], because they are structurally most
conserved by evolution. This also allows for the application of these modelled regions
for drug design purposes.
Homology modelling with MODELLER MODELLER belongs to the group of
methods that model a proteins structure by satisfaction of spatial restraints [Sali &
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Figure 2.1: Accuracy and application of protein structure models. Shown are the
different ranges of applicability of comparative protein structure modelling, threading,
and de novo prediction; the corresponding accuracy of protein models; and their sample
applications. From [Baker & Sali, 2001].
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Blundell, 1993]. Protein modelling with MODELLER starts with a sequence alignment
of the target protein with related known 3D structures. In the initial phase of the
modelling process, restraints on the target protein are derived based on the sequence
alignment with the template structures. Further restraints are derived from statistical
analysis of the relationships between various general features of the protein structure,
i.e. the distributions of distances between Cα atoms, residue solvent accessibilities or
side-chain torsion angles. These features are associated between the target and the
homologous template protein(s). Thus, the conformation of a particular residue can
be restrained according to the residue type, the conformation of an equivalent residue
in a related protein, and the local similarity between the proteins. These restraints
are expressed in terms of conditional probability density functions (pdf). Each of these
pdfs is a smooth function which describes the distribution of the considered feature as
a function of the related variables. To enforce proper stereochemistry, these individual
pdfs are combined with terms from the CHARMM force field [Brooks et al., 1983] (also
expressed as pdf) to a molecular probability function:
F = F (R) = −ln
[∏
i
Pi(fi, Ii)
]
=
∑
i
Ei(fi, ai) (2.1)
where −lnPi = Ei. R are the Cartesian coordinates of all atoms, Pi is a conditional
probability density function (pdf) for a geometric feature fi that depends on information
Ii, which is derived from the template protein structure and associated restraints from
analysis of various features of protein structures. Ei is an energy term, and ai are
general parameters related to Ii.
The model is obtained by optimising the objective function F by use of the variable
target function method [Braun & Go, 1985], employing methods of conjugate gradients
and molecular dynamics with simulated annealing [Clore et al., 1986]. Local restraints
are considered first, global restraints subsequently.
A consequence of the probability density functions is that side-chains adopt similar con-
formations as in the template structure in regions which are conserved in the sequence
alignment. By entering the optimisation with slightly different structures, models with
differing structure can be obtained, which can reflect the conformational flexibility of
the target protein in those regions which are different in the sequence alignment.
One major strength of MODELLER is that constraints or restraints derived from a
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number of different sources can be added to the homology-derived restraints. For ex-
ample, restraints could be provided by rules in terms of secondary structure packing,
analyses of hydrophobicity, NMR experiments, etc. In this way, a homology model,
especially in difficult cases, can be improved by making it consistent with available
experimental data and with general knowledge about protein structures. Accordingly,
it should in principle be possible to include ligand-based information into the homology
modelling process. Within MODELLER, there are several possibilities to accomplish
this task: for example, upper and lower boundaries for bond distances can be con-
strained between protein and ligand atoms or interactions can be approximated by
van-der-Waals, Coulomb or H-bond potentials. Another possibility, which was fol-
lowed in this study, is to approximate knowledge-based atom-pair potentials between
protein and ligand atoms in terms of cubic splines to describe and regard their mutual
influence in the homology modelling process.
2.1.3 Evaluation of protein structures
Once a protein model is constructed, it is important to assess its validity for the
following modelling steps. Several approaches exist which evaluate the quality of a
protein model. For the detection of correct protein models, an energy function is
required, which efficiently identifies near-native structures. The principles of currently
applied energy functions can be divided into physical and knowledge-based approaches
[Wallner & Elofsson, 2003].
In physical energy functions, energy functions are used which were originally developed
for 3D structure refinement and molecular dynamics simulations, such as CHARMM
[Brooks et al., 1983] or Amber [Weiner et al., 1986]. Additionally, terms accounting
for effects not considered implicitly in the energy function, are generally included into
the scoring function. For example, Dominy et al. recently used the generalised Born
solvation model [Still et al., 1990] to describe solvent effects [Dominy & Brooks, 2002].
Knowledge-based energy functions are calculated as the difference between features of a
random protein model and observations from real protein structures. Most frequently,
preferences for interacting protein residues are considered (e.g. [Jones et al., 1992; Sippl,
1993; Huang et al., 1995]), measuring the distances or simply counting the number
of contacts. Some approaches are based on atom-type preferences [Colovos & Yeates,
1993; Samudrala & Moult, 1998; Melo & Feytmans, 1997, 1998; McConkey et al., 2003].
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Another popular knowledge-based approach is Eisenberg’s 3D profiles method [Bowie
et al., 1991; Luthy et al., 1992; Eisenberg et al., 1992]. It calculates for each amino acid
in the proposed structure (1) the total surface area of a residue that becomes buried in
the protein, (2) the fraction of the side-chain area that is covered by polar atoms and
(3) the local secondary structure. These three parameters are then used to allocate
the residue to one of eighteen environment classes. Each amino acid is assigned a score
that reflects its compatibility with the amino acids in the local environment.
Finally, analysis of protein models is often performed by examining the structure and
analysing any significant deviation from the norm, e.g. by calculating a Ramachandran
plot. Another basic test is to use Procheck [Laskowski et al., 1993] or What Check
[Hooft et al., 1996] which assess the stereochemical quality of a protein structure.
They analyze how common, or, conversely, how unusual the geometry of the residues
in a given protein structure is, as compared with stereochemical parameters derived
from well-refined, high-resolution crystal structures. The program PROVE (PROtein
Volume Evaluation) [Pontius et al., 1996] measures deviations from standard atomic
volumes as a figure-of-merit for protein structures.
2.2 Prediction of protein-ligand interactions
Two aspects are of utmost importance for successful computer-aided structure-based
drug design: generating near-native protein-ligand configurations (docking), the iden-
tification of those binding modes that agree best to the experimentally given situation,
and a computational translation of the obtained protein-ligand geometries into approx-
imate estimates of the binding affinity (scoring). These issues will be addressed in the
following, discussing in some more detail those methods which were applied in this
study (FlexX, AutoDock, and DrugScore), and considering in particular the problem
of ligand-induced protein flexibility.
2.2.1 Ligand docking
The goal of docking is the computing of non-covalent protein-ligand complexes. Given
the structures of a protein and a ligand, the task is to predict the structure of the formed
complex. This is the so-called ”docking problem”. Assuming that the native geometry
16 2.2 Prediction of protein-ligand interactions
of the complex corresponds to the global minimum of the binding free energy, docking
can actually be regarded as an energy optimisation problem [Totrov & Abagyan, 2001],
concerned with the search of the lowest-free energy binding mode of a ligand within a
given protein binding-site. The macromolecular nature of the protein and the fact that
binding occurs in aqueous solution complicate the problem significantly because of the
high dimensionality of the configuration space and the considerable complexity of the
energetics governing the interactions. Accordingly, heuristic approximations are fre-
quently applied to render the problem tractable within a reasonable time frame. The
development of docking methods is therefore also concerned with making appropri-
ate assumptions and finding acceptable simplifications that still provide a sufficiently
accurate and predictive model for protein-ligand interactions [Sotriffer et al., 2002a].
Comprehensive overviews on docking algorithms and programs have been given by
Sotriffer et al. [Sotriffer et al., 2002a] and Halperin et al. [Halperin et al., 2002].
The following paragraphs give an introduction into two docking programs (FlexX and
AutoDock), which have been used in the context of this work.
Approaches for docking into rigid protein structures
FlexX In FlexX [Rarey et al., 1996a, 1997, 1996b; Kramer et al., 1999], interaction
types and geometries according to Bo¨hm [Bo¨hm, 1992a,b] and Klebe [Klebe, 1994]
describe the protein ligand interactions. Each interacting group of the molecule to
be docked is assigned an interaction type and a corresponding compatibility. Possible
interaction types are geometrically restricted hydrogen bonds, interactions between
metals and metal acceptors, and hydrophobic interactions, for example those between
phenyl rings and methyl groups. For each group capable to form an interaction, a
special contact geometry is defined by placing an interaction surface around the centre,
usually as part of a sphere. Two groups form an interaction if the interaction centre of
one group coincides with the interaction surface of a counter group.
Conformational ligand flexibility is modelled discretely [Klebe &Mietzner, 1994] using a
set of preferred torsion angles about acyclic single bonds taken from a library which was
compiled from torsional fragments extracted from the Cambridge Structural Database
[Allen et al., 1979]. Multiple conformations for ring systems are computed with the
program CORINA [Gasteiger et al., 1990; Sadowski & Gasteiger, 1993; Sadowski et al.,
1994].
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The docking algorithm in FlexX is based on an incremental construction strategy
consisting of three phases: In the first phase (base selection), the base fragment of
the ligand is selected which is then placed into the active site of the protein (base
fragment placement). Finally, the ligand is reconstructed in an incremental fashion,
starting from different placements of the base fragment (complex construction). Upon
connecting additional fragments, new interactions are screened and the best partial
solutions based on the ranking of a scoring function are hooked up until the ligand is
completely constructed.
The docking algorithm is relatively sensitive to the selection and placement of the base
fragment. If the geometry of a fragment of a molecule to be docked is known (e.g.,
from a similar ligand crystallised in the target protein), a useful option is to place
the referring fragment manually into the binding pocket via the mapref command.
This reduces the run time of the docking procedure and increases the probability of
predicting the correct binding mode of the ligand.
Another possibility to include knowledge about protein-ligand interactions a priori,
as user-defined constraint, into the docking process can be realised by FlexX-Pharm
[Hindle et al., 2002], an extended version of FlexX. The constraints are determined by
selected FlexX interactions and inclusion volumes. They guide the docking process to
produce a set of docking solutions with particular properties. By applying a series of
look-ahead checks during the flexible construction of ligand fragments within the active
site, FlexX-Pharm determines which partially built docking solutions can potentially
obey the constraints. Solutions that will not obey the constraints are discarted as early
as possible, thus decreasing the calculation time and enabling new docking solutions
to emerge.
AutoDock Instead of explicit interaction types and geometries, as realised in FlexX,
AutoDock [Goodsell & Olson, 1990; Morris et al., 1996, 1998] uses grid representations
of the protein structure.
The binding pocket of the protein is represented by an affinity grid which is calculated
for each type of atom occurring in the ligand, typically carbon, oxygen, nitrogen and
hydrogen, as well as a grid of the electrostatic potential.
These maps then serve as look-up tables for the calculation of the interaction en-
ergy or scoring value during the flexible docking of the ligand. The search can be
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performed using one out of three possible search strategies: Monte Carlo simulated
annealing, a traditional genetic algorithm, and a Lamarckian genetic algorithm. The
latter Lamarckian genetic algorithm is the combination of a traditional genetic algo-
rithm with a local search method to perform energy minimisation. At each generation,
a user-defined fraction of the population is subjected to such a local minimisation. The
Lamarckian genetic algorithm was observed to be the most efficient and reliable of the
three methods [Morris et al., 1998].
Approaches for docking considering protein flexibility
Most docking approaches treat the protein rigid during the docking process, which is a
reasonable simplification if the protein binding pocket is sufficiently rigid and does not
exhibit significant side-chain rearrangements upon ligand binding. However, in some
cases it cannot be justified to neglect protein flexibility [Teague, 2003; Davis & Teague,
1999; Bursavich & Rich, 2002; Najmanovich et al., 2000; Carlson & McGammon, 2000;
Verkhivker et al., 2000]: if the system under consideration is known to be flexible or if
the available protein structure is not well resolved, as, for example, in the case of a ho-
mology model. A study, recently performed by McGovern et al. [McGovern & Shoichet,
2003], clearly demonstrated that the success of molecular docking depends significantly
on the particular representation of the receptor used in a screen. In their experiment,
the best enrichment was produced by docking into the ligand-bound receptor structure
instead of docking into the uncomplexed structure or a homology model. The authors
note, however, that a receptor determined in one particular ligand-bound conformation
could possibly bias the docking screen, preventing the discovery of ligands much differ-
ent from the ligand already captured in the complex. The same conclusion was drawn
by Murray et al., who successfully identified the correct ligand conformation (for three
test enzymes) in 79 % of the cases as the lowest energy configuration when the enzyme
structure was provided in terms of the crystal structure actually complexed by the
tested ligand. Their methodology only docks however in 49 % of the cases successfully
when the ligand is screened against an enzyme crystal structure extracted from a com-
plex with another ligand [Murray et al., 1999]. As a consequence, possible adaptations
of the protein binding-site upon ligand binding have to be considered in a docking run,
in order to avoid false-negative results. As an alternative or pragmatic compromise the
scoring functions used to subsequently rank the generated binding modes have to be
tailored in a way to tolerate such structural deficiencies.
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A possible approach for considering structural variations of proteins is to dock into an
ensemble of protein structures showing deviating active site conformations. As shown
previously, by averaging structural details and, hence, smoothing the energy landscape,
it is possible to circumvent local minima of an otherwise rugged energy surface. This
results in a faster convergence of the docking problem [Trosset & Scheraga, 1998;
Vakser, 1996]. Furthermore, the treatment of protein structures as ensembles has the
advantage that this compensates for some of the structural deficiencies and inequality
using only one single protein model. In addition, potential protein flexibility induced
upon ligand binding [Ma et al., 1999] can be accounted for.
Several approaches have been developed that can dock ligands into ensembles of protein
structures:
• Knegtel et al. used (1) simple and (2) energy-weighted averaging for the de-
scription of interactions between a ligand and each receptor structure from the
ensemble by generating composite grids. These were subsequently used for scor-
ing within DOCK [Knegtel et al., 1997]. Both averaging methods performed
equally well in their test cases. O¨sterberg et al. extended this approach by test-
ing four methods for merging multiple ensemble entries into one single grid-based
lookup table of interaction energies using AutoDock [O¨sterberg et al., 2002]. In
their test set, mean and minimum averaging methods perform poorly, but two
weighted averaging methods yield consistent and accurate ligand docking.
• Another approach to handle protein flexibility is realised in FlexE, [Claussen
et al., 2001] a variant of the FlexX program. FlexE is based on a united protein
description generated from an ensemble of superimposed structures of an ensem-
ble. For the structurally deviating parts of the protein, discrete alternative con-
formations are explicitly taken into account during the incremental construction
of the ligand in the binding-site. These geometric alternatives are then combi-
natorially joined to create new valid protein structures. Thus, conformations of
the protein are not limited to those explicitly present in the ensemble.
• DragHome was especially developed for the purpose of ligand docking into
approximate homology-modelled proteins [Schafferhans & Klebe, 2001]. The
binding-site models are analysed in terms of putative interaction sites, which are
predicted by LUDI [Bo¨hm, 1998; Bo¨hm & Klebe, 1996; Bo¨hm, 1994b,a, 1993,
1992a,b]. They are then translated via Gaussian functions into arithmetically or
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geometrically averaged binding-site descriptions representing physico-chemical
properties. The use of ”soft” Gaussian functions to describe protein-ligand inter-
actions smoothes the potential energy surface and, thus, takes into account the
limited accuracy of the modelled structures for the purpose of docking. The lig-
ands are similarly expressed by property densities based on Gaussian functions.
The docking is performed by maximising the overlap between the functional de-
scriptions for ligand and binding-site representations using the ligand alignment
program SEAL [Kearsley & Smith, 1990; Klebe et al., 1994b, 1999].
• In SLIDE, ligand and receptor flexibility is introduced after the initial ligand
placement. Collisions are resolved by using mean field theory [Jackson et al.,
1998; Koehl & Delarue, 1994, 1996] to select rotations about single bonds in the
ligand and the protein side-chains, reducing a maximal number of collisions by
minimal conformational changes of both binding partners [Schnecke et al., 1998;
Schnecke & Kuhn, 2000].
Another approach for ligand docking, accommodating receptor flexibility, was recently
described by Lin et al. [Lin et al., 2002, 2003]: Initially, a long molecular dynamics
(MD) simulation of the uncomplexed receptor is performed to sample sets of protein
conformations. The second phase of their ”relaxed complex” scheme involves rapid
docking of candidate inhibitors into a large ensemble of MD snapshots, followed by a
more accurate scoring using the MM/PBSA (Molecular Mechanics/Poisson Boltzmann
Surface Area) approach [Kollman et al., 2000; Massova & Kollman, 2000; Srinivasan
et al., 1998] to find the best ligand-receptor complexes.
It should be noted that (to our knowledge) all above-mentioned approaches still await
successful applications for finding a novel ligand for a flexible protein system. On the
one hand, this is probably due to the fact that some methods are computationally too
demanding to perform a virtual screening since the dimensionality of the configuration
space is significantly increased; on the other hand, a reliable scoring scheme to identify
the native protein-ligand configuration may still be missing.
2.2.2 Affinity prediction
In the following section, a brief overview over general aspects concerning affinity predic-
tion will be given. A detailed description of the scoring function DrugScore is provided,
2.2 Prediction of protein-ligand interactions 21
which is used in the context of this work. For a more comprehensive overview over cur-
rent approaches for affinity prediction, the reader is referred to refs [Gohlke & Klebe,
2002a; Sotriffer et al., 2002a].
Affinity prediction in case the protein structure is given
General overview The strategy followed in rational drug design depends on whether
the three-dimensional structure of the biological target molecule is known or not. If
the structure of a target receptor is available, information about the binding-site and
principles of protein-ligand interactions can be used to estimate the binding affinity of
a given protein-ligand orientation obtained by crystal structure analysis or by compu-
tater docking (see section 2.2.1). Accurate and fast scoring is important both for the
determination of the correct binding modes from a sample of protein-ligand configu-
rations and for the ranking of a large sample of different ligands with respect to their
affinity.
Three main classes of scoring functions can be distinguished: force-field based methods,
empirical scoring functions, and knowledge-based methods. Force-field based methods
[Ewing et al., 2001; Morris et al., 1998; Jones et al., 1997] calculate binding affinity
using energy functions developed for 3D structure refinement and molecular dynamics
calculations, usually employed in free energy perturbation (FEP) methods [Kollman,
1993, 1996]. Although these methods are relatively accurate, they are computationally
demanding and limited to structurally similar ligands. Empirical scoring functions ap-
proximate the free energy of binding in terms of a ”master equation” as a weighted
sum of several factors corresponding to arbitrary enthalpic and entropic contributions.
The coefficients are optimised by fitting the derived functional form to observed bind-
ing data of a training set of protein-ligand complexes with known structure [Eldridge
et al., 1997; Murray et al., 1998; Bo¨hm, 1994a, 1998; Wang et al., 1998, 2002; Jain,
1996; Head et al., 1996]. The most recently developed approaches are the so-called
knowledge-based scoring functions [Muegge & Martin, 1999; Muegge, 2000, 2001; De-
Witte & Shakhnovich, 1996; Mitchell et al., 1999a,b; Gohlke et al., 2000a,b; Wallquist
et al., 1995; Verkhivker et al., 1995]. They are based on the idea that a sufficiently large
data sample can serve to derive rules and general principles inherently stored in this
knowledge base. Accordingly, the development of a knowledge-based scoring function
at an atomic level is based upon observed frequency distributions of typical interac-
tions in experimentally determined structures: in any system, only those interactions
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that are close to the frequency maxima of the interactions in the knowledge base are
considered as favourable. Using the concept of the ”inverse Boltzmann law” [Sippl,
1995], the frequency distributions of interatomic interactions, derived from protein
crystal structures, are converted into ”potentials of mean force” or ”knowledge-based
potentials”.
A pragmatic strategy to enhance the hit rate from a docking screening is to reevalu-
ate the best docked binding poses with multiple scoring functions, a procedure called
consensus scoring [Charifson et al., 1999; Clark et al., 2002]. Only the compounds
scored at the top commonly by all scoring functions are further considered. Therefore,
in a statistical sense, consensus scoring is more robust and accurate than any single
scoring procedure [Wang & Wang, 2001]. It was indeed shown by Wang et al. [Wang
et al., 2003] and Bissantz et al. [Bissantz et al., 2000] that combining any two or three
scoring functions clearly enhances the success rate to retrieve active hits. However,
when applying consensus scoring, one should keep in mind that, even so the number
of false positives can be reduced, the number of true positives might also decline.
DrugScore In the following, the knowledge-based scoring function DrugScore, de-
veloped in our lab [Gohlke et al., 2000a] will be briefly described. It was used in the
present work to predict and score the binding modes of protein-ligand complexes for
the development of our approach for ligand-supported homology modelling of protein
binding-sites (MOBILE) (chapter 3). Furthermore, we applied DrugScore to rank the
putative hits in our database screen for the neurokinin-1 receptor (chapter 4).
For the development of DrugScore, the structural information of 1376 crystallograph-
ically determined protein-ligand complexes was retrieved from the database ReliBase
[Hendlich et al., 2003; Gu¨nther et al., 2003; Bergner et al., 2001]. Subsequently, this in-
formation was converted into statistical preferences based on 17 atom types [Hendlich,
1998]. The distance-dependent atom-pair distributions gi,j(r)/g(r) for the individual
atom types ij are divided by a common reference state which is taken as the average
over the distance distributions of all atom pairs g(r) =
∑∑
gi,j(r)/i ∗ j. To consider
only direct protein-ligand contacts, the upper sample radius has been set to 6 A˚ (see
Fig. 2.2).
At this distance, no further atoms, e.g. of a water molecule, can mediate a protein-
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Figure 2.2: Knowledge-based pair potentials between polar/ charged (O.co2-N.pl3
(green), O.3-O.co2 (red), O.3-O.3 (blue)) ligand and protein atoms (left) and non-
polar/aromatic (C.ar-C.ar (red), C.3-C.3 (blue)) atom pairs (right) as a function of
distance R, calculated according to equation 2.2. The first atom-type symbol refers to
the ligand, the second to the protein. From [Gohlke et al., 2000a].
ligand interaction. The individual potentials have the form
Eij(r) = −kT ((lngi,j(r)
g(r)
)− ln g(r)) (2.2)
These pair potentials are applied together with potentials depending on single (protein
or ligand) atom types that express the propensity of an atom type to be buried within a
particular protein environment upon complex formation. Contributions of these surface
potentials and the pair potentials are weighted equally in the final scoring function.
Affinity prediction when the protein structure is unknown
If the three-dimensional structure of the target protein is unknown, ”quantitative struc-
ture activity relationships” (QSAR methods) [Kubinyi, 1993; Kubinyi et al., 1997] can
be used to establish a relationship between molecular structure and biological activity
within a series of active compounds. These models do not only explain the relative
differences among the observed affinities, but also allow for an affinity prediction of
novel compounds.
The most widely used application of 3D-QSAR in molecular modelling and drug design
is the comparative molecular field analysis (CoMFA), first described by Cramer et al.
[Cramer et al., 1988].
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Given a series of ligand molecules binding within an affinity range of four orders of
magnitude to the target protein, the first step is to find a spatial orientation of the lig-
ands which is representative for the differences in the binding geometry at the protein
binding-site. If the protein structure is not given, the ligands are mutually superim-
posed in their assumed active-site conformation, e.g., by applying a strategy such as
the ”active analog approach” [Marshall et al., 1979]. It compares flexible compounds
with rigid analogs in particular by mutually excluding part of the accessible confor-
mational space due to structural restrictions. It finally suggests geometries for all
ligands in the data set that could possibly correspond to the active-site conformation.
Several approaches have been developed which accomplish the task of superimposing
ligand molecules while maximising their spatial overlap with respect to similar physico-
chemical properties [Lemmen & Lengauer, 2000].
Assuming that a reasonable ligand alignment has been generated, a sufficiently large
lattice box is positioned around the molecules with a predefined grid spacing. Field val-
ues representing atomic or physico-chemical properties are calculated at each grid point.
Subsequently, field properties are correlated with differences in the dependent target
property, for example, the binding affinity. In its original implementation, Lennard-
Jones- and Coulomb-interactions energies are calculated for all molecules of the data
set at the grid points. The general form of the QSAR equation results to:
Affinityn = k + α1Sn,1 + ...+ αMSn,M + β1En,1 + ...+ βMEn,M (2.3)
The indices 1, 2, ..., M reflect the respective grid points, and Sn,1, ..., Sn,M and
En,1, ..., En,M describe steric and electrostatic energies at these points. The coeffi-
cients α1, ..., αM and β1, ..., βM are obtained from a system of linear equations by
partial least-squares (PLS) analysis [Geladi & Kowalski, 1986; Wold et al., 1993].
Binding affinities of new molecules not included in the training set can be predicted
using the derived model.
Despite the straightforward definition of CoMFA, there are a number of serious prob-
lems and possible pitfalls [Kubinyi, 1993; Thibaut et al., 1994]. One alternative to
CoMFA is the comparative molecular similarity indices analysis (CoMSIA) [Klebe
et al., 1994a]. Here, Gaussian functions are used to describe steric, electrostatic, and
hydrophobic similarities. Similarly, hydrogen-bond donor and acceptor properties are
considered [Klebe et al., 1999]. Compared to CoMFA, this approach avoids partic-
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ularly steep potentials next to molecular surfaces. Thus, similarity indices are also
determined close to and even in the area occupied by the ligands.
2.2.3 Approaches combining protein and ligand-based
procedures
When the 3D structure of a target protein is given, drug design usually applies
structure-based techniques, while ligand-based information is often neglected. On the
other hand, if affinity data for a series of ligands is available, generally ligand-based
approaches are applied to discover and optimise novel compounds. If the corresponding
structure of the target protein is available, this knowledge remains often unused apart
from the assistance to produce a reasonable ligand alignment. In many cases, it could
be beneficial to combine protein- and ligand-based approaches, and use the strength of
one approach to overcome shortcomings of the other method, or, at least, to use both
strategies to mutually confirm results from these complementary approaches. The
following sections present examples from literature, where ligand- and protein-based
strategies were combined in order to obtain more reliable predictions for protein-ligand
interactions.
Combination of protein- and ligand-based information for molecular
docking
The docking program FlexX [Rarey et al., 1996a, 1997, 1996b; Kramer et al., 1999]
(see section 2.2.1) offers the option to place the base fragment for the incremental
construction algorithm of the ligand manually into the binding pocket via the mapref
command. However, at the moment this option only works for small, relatively rigid
fragments. A further option, realised in FlexX-Pharm [Hindle et al., 2002], is the
possibility to incorporate more generic information about important characteristics of
protein-ligand binding modes into the docking calculation in terms of pharmacophore-
type constraints and restraints.
A so-called ”similarity-driven approach to flexible ligand docking” was presented by
Fradera et al. [Fradera et al., 2000]. Given a reference ligand or a pharmacophore
positioned in the protein active site, the method allows inclusion of a similarity term
during docking. Using the docking program DOCK 4.0 [Ewing & Kuntz, 1997; Ewing
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et al., 2001] for the placement of the ligand in the protein binding-site, the similarity
program MIMIC [Mestres et al., 1998] is included as a module for the calculation of
similarity indices. MIMIC either (1) corrects docking energy scores at certain steps of
the ligand incremental construction or (2) applies similarity corrections at the end of
the calculation.
Combination of protein- and ligand-based information for affinity
prediction
Combination of protein- and ligand-based information is also possible for the prediction
of binding affinities. A first step in this direction is the usage of the protein structure,
along with a docking protocol, to guide the molecular alignment of ligands in a com-
parative molecular field analysis (CoMFA). Novel ligands could then be searched by
first docking them into the protein structure and then predicting their affinity with
respect to the established CoMFA model. This procedure has already been applied
by several groups (for example see [Gamper et al., 1996; Bursi & Grootenhuis, 1999;
Lozano et al., 2000; Cho et al., 1996; Holloway et al., 1995; Tokarski & Hopfinger, 1997;
Vaz et al., 1998; Sippl, 2003]).
This latter approach, which could be termed ”protein-supported ligand-based drug
design”, can also be applied if the structure of the target protein is not available but
sequentially related proteins with known 3D-structure have been determined. In such
a situation, a homology model can be generated which guides the docking process of
the ligand molecules [Jalaie & Erickson, 2000; Schafferhans & Klebe, 2001; Kim, 1998]
(see also next section). As an advantage, the significance of the generated CoMFA
model can also serve to estimate the quality of the generated homology model.
Wade et al. used selected interaction energy components to include information from
the protein into a 3D-QSAR model. Their COMBINE approach [Ortiz et al., 1995,
1997; Wang & Wade, 2001] quantifies ligand-receptor interaction energies by molecular
mechanics in terms of van der Waals and Coulomb contributions per residue, followed
by a PLS analysis in order to derive a 3D-QSAR model. Other similar approaches have
also been described [Kurinov & Harrison, 1994; Kulkarni & Kulkarni, 1999; Rognan
et al., 1999; Grootenhuis & van Galen, 1995; McCarthy et al., 1997].
Another procedure which considers protein information not only for the suggestion of
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a meaningful ligand alignment but also includes information about the surrounding
protein environment in the potential field calculations, is the recently developed AF-
MoC approach [Gohlke & Klebe, 2002b]. AFMoC tailors protein-specifically adapted
DrugScore pair-potentials to one particular protein by considering additional ligand-
based information in a CoMFA-type approach. As in CoMFA, the results of the analysis
can be interpreted in graphical terms by contribution maps, and binding affinities of
novel ligands are predicted by evaluating the established 3D QSAR equation. Com-
pared to the original, solely ligand-based CoMFA approach, the AFMoC method has
the following striking advantage: Whereas in CoMFA a large data set of structurally
diverse training compounds spreading over a sufficient range of binding affinities is nec-
essary, AFMoC is able to generate predictive models also with a fairly limited number
of ligands, spanning over a lower range of affinity. As a further advantage, AFMoC
allows the user to gradually move from general knowledge-based potentials to protein-
specifically adopted ones, depending on the confidence in the protein structure (e.g. in
the case of a homology model) and the amount of ligand data available for training.
Whereas CoMFA can only interpolate among the data points defined by the ligands
of the data set, AFMoC can still extrapolate to some extent into areas not yet experi-
enced by any of the training set compounds since in these areas the original DrugScore
potentials generate a reasonable predictive power.
Combination of protein- and ligand-based information for homology
modelling
The incorporation of ligand information explicitly into the protein modelling process
has not yet been described in literature. Instead, ligand information was used to
subsequently refine an already existing homology model by energy minimisation or
molecular dynamics. Furthermore, ligands are docked into homology models and the
relevance of the docking solution or the significance of a CoMFA model based on docked
ligands served as validation criterion to assess the generated protein model. For a more
detailed overview, see section 2.3.
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2.3 Examples of homology modelling for the
purpose of structure-based drug design
Several studies have been described in literature where homology models of proteins
have been used to explain putative interactions between a protein and ligands ([Bour-
don et al., 1997; Lozano et al., 1997; Garcia-Nieto et al., 2000; Zhang et al., 2001;
Marhefka et al., 2001; Le Novere et al., 2002; Gieldon et al., 2001; Escherich et al.,
2001; Bathelt et al., 2002; Lopez-Rodriguez et al., 2001; Bissantz et al., 2003; Vaidehi
et al., 2002; Gouldson et al., 1997; Moro et al., 1998b,a]). In some cases, the generated
models were used for the design of new potent inhibitors ([Tiraboschi et al., 1999; Rong
et al., 2002; Kiyama et al., 1999]).
However, in none of these examples ligand information was explicitly considered during
the modelling of the protein. Usually, a homology model based only on one or more
template structures is initially produced and subsequently the ligand(s) are placed
into the modelled binding pocket. This is accomplished either manually or using an
automatic docking tool. Another strategy follows the superimposition of template and
model followed by the merging of the coordinates of a ligand as adopted in the template
structure into the model. In most cases, the resulting complexes are further optimised,
e.g. by using a molecular dynamics protocol, which, to some extend, uses the ligand
information for the protein modelling, at least in terms of a local optimisation.
In another approach, ligand information was used by Jansen et al. for modelling the
serotonin 5 −HT1A receptor. The optimisation was performed with the minireceptor
modelling program Yak [Vedani et al., 1993] based on an extracted active site of a
homology model using three high-affinity ligands [Jansen et al., 1997].
An important task in model-building protein-ligand complexes is the quality assessment
of the produced models, in particular if different orientations of active site residues are
possible. This step is usually performed by visually analysing the interaction geome-
try between protein and ligand functional groups. This consecutive procedure appears
rather inefficient. Only a few approaches assess the quality of the generated complexes
in a more sophisticated way: Johnson et al. created a library of protein models that
are subsequently screened by rigid ligand docking. The more relevant protein models
achieve better scored docking solutions, and the quality of the generated binding modes
is used to select the most relevant models [Johnson et al., 2003]. This approach has
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been applied to the modelling of Fv antibody fragments. Results were compared to the
known crystal structures. However, it requires experimental data about the conforma-
tion of the docked ligand. Bissantz et al. evaluated their generated homology models
(agonist and antagonist bound models of three human G protein coupled receptors) by
retrieving known agonists and antagonists via docking from a database assembled by
such entries and additional randomly collected ”drug-like” compounds [Bissantz et al.,
2003]. Jalaie et al. developed a homology model of spinach photosystem II. After
docking inhibitors, a highly predictive CoMFA model was derived from the resulting
alignment. It helped to score the quality of the homology model [Jalaie & Erickson,
2000]. A similar approach was followed in our group by Schafferhans and Klebe. Struc-
turally distinct thrombin inhibitors were docked onto models of thrombin generated
from a set of serine proteases with 28 up to 40 % sequence identity. Compared to the
crystal structures of actually known thrombin complexes, ligand binding modes were
obtained with an average rms deviation of 1.4 A˚ [Schafferhans & Klebe, 2001]. Based
on the generated alignment of 88 thrombin inhibitors, a significant 3D QSAR model
could be established.
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3 Development of an approach for
Ligand-supported Homology Modelling
of Protein Binding Sites using
Knowledge-based potentials
3.1 Strategy and computational realisation
3.1.1 General overview
Below, we describe in detail how we complement data about related proteins with
information about the binding modes of bioactive ligands to generate more realistic
homology models of protein binding-sites. A schematic overview of our strategy, which
was initiated by the development of the DragHome concept and is followed by MO-
BILE (Modelling binding-sites including ligand information explicitly), is given in Fig.
1.4. Starting with the (crystal) structure of one or more template proteins, several pre-
liminary homology models of the target protein are generated (step 1). After placing
one or more ligands, known to bind to the target protein, into an averaged binding-
site representation of the generated binding-site models (step 2), the protein models
are generated, now considering explicitly the docked ligand(s) (step 3a). After scoring
the thus generated complexes with DrugScore, a final model is obtained by selecting
the model which explains best the observed ligand binding (affinities) (step 3b). The
modelled complexes can be further refined considering the composite picture of the
best side-chain conformers taken from different models and minimising the side-chain-
to-ligand interactions using a common force-field (step 4).
3.1.2 Step 1: Generation of preliminary protein models
The program MODELLER [Marti-Renom et al., 2000; Sali & Blundell, 1993; Fiser
et al., 2000] is used to generate initial homology models in the first step of our ap-
proach (Fig. 1.4). MODELLER generates protein 3D structures by satisfying spatial
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restraints imposed by the sequence alignment with the template structure and applying
the terms of the CHARMM-22 force-field [Brooks et al., 1983]. A 3D protein model is
obtained by optimising the molecular probability density function while simultaneously
minimising input restraint violations. To guarantee sufficient conformational sampling
of each active site residue, several homology models are generated in this step. Prelim-
inary tests showed that a number between 10 and 100 models provides a satisfactory
sampling. To optimise the local interactions, all models obtained are subjected to a
crude simulated annealing refinement protocol available in MODELLER.
3.1.3 Step 2: Placing the ligand(s) into the homology models
As a next step, proper ligand orientations need to be obtained. Three scenarios are
described, characterised by a decreasing amount of experimental information available:
1. One or more ligands are known to bind to the target protein, and the complex
crystal structures with the related template proteins are available. It can be
assumed that the ligand binding modes are similar in the target and the template
protein. Accordingly, ligands are then transferred among these structures keeping
their orientation as a restraint for the subsequent modelling process.
2. One or more ligands are known to bind to the target, however, no complex
crystal structure with the template is available. In this case, the ligand(s) can
either be placed into the template protein structure by docking, and the resulting
orientation can then be used to restrain the following protein modelling process.
Alternatively, the coordinates of a similar ligand, crystallised together with the
template protein, serves as a reference to restrain the protein modelling process.
The known ligand is then transferred into the modelled proteins as described in
the following section.
3. If no structural information about ligands binding to the template protein is
available, one or more ligands (known to bind to the target protein) are docked
into the homology models of the target protein. Since a homology modelling
program generates a set of different models with similar energies, ligand docking is
attempted as a placement into ensembles of the modelled protein structures. Two
different approaches were combined to place ligands into ensembles of model-built
protein structures. Following Sotriffer et al. [Sotriffer et al., 2002b], DrugScore
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potential grids were calculated in the binding pocket of each homology model by
evaluating protein-ligand interactions between a predefined probe atom, placed at
each grid point, and the surrounding protein environment. At short interatomic
distances, the pair potentials were supplemented by a Gaussian-type repulsive
term as described by Gohlke et al. [Gohlke & Klebe, 2002b]. Grids of identical
size were used for each homology model. Their dimensions were adjusted to fully
embed the ligand in its crystallographically determined binding mode with an
additional margin of at least 4 A˚. The ligands were then docked into the merged
binding pockets using AutoDock 3.0 after averaging the grid maps representing
the potential energy using the clamped grid method as described by Osterberg
et al. [O¨sterberg et al., 2002]. The Lamarckian genetic algorithm was applied
using the docking protocol as given by Sotriffer et al. [Sotriffer et al., 2002b].
3.1.4 Step 3a: Incorporating ligand information into the
homology modelling process
Having placed the ligand(s) in a near-native orientation into the consensus binding-site
of the modelled protein, new models are generated using MODELLER which addition-
ally incorporate information about these ligand(s). During this modelling step, the
ligands are kept fixed in space. The presence of the ligand(s) is included into the ho-
mology modelling process in terms of user-defined restraints. Scaled DrugScore pair
potentials are added to the MODELLER force-field to provide information about the
interactions experienced between fixed ligand(s) and flexible protein atoms. The scal-
ing of DrugScore potentials with respect to the MODELLER force-field is described in
detail in the section 3.4.3. No further interactions between protein and ligand atoms
are considered. To make the DrugScore potentials suitable for a minimisation proce-
dure, we approximate them by cubic splines (assigning a range from 0 to 6 A˚ and a
bin size of 0.1 A˚). This can be realised through the MODELLER interface. To include
the repulsive interactions at short distances, the above-mentioned Gaussian repulsion
term has been added [Gohlke & Klebe, 2002b].
The protein modelling process is not necessarily restrained to one ligand. If several
ligands are known to occupy distinct parts of the binding pocket, a combination to a
composite ”super-ligand” can be attempted.
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3.1.5 Step 3b: Scoring the generated models
Having generated a set of ligand-supported homology models, the next objective is to
identify the best one(s). Quality assessment of homology models usually applies fold
plausibility criteria or tries to assess local features considering protein atom interactions
only [Bowie et al., 1991; Colovos & Yeates, 1993; Dominy & Brooks, 2002; Eisenberg
et al., 1992; Laskowski et al., 1993; Luthy et al., 1992; Melo & Feytmans, 1998; Simons
et al., 1999; Wang et al., 1995b,a]. The primary interested in the scope of this Thesis is
to obtain near-native models of protein binding-sites, accordingly the standard proto-
cols for evaluating protein homology models would be insensitive and non-conclusive.
Also, the MODELLER objective function would not provide a proper criterion, as it
assesses matching with all requested input restraints. Assuming that the modelled
protein-ligand geometry corresponds to a near-native geometry, we require a scoring
function suitable to evaluate protein-ligand interactions. As DrugScore shows good
performance to identify near-native ligand poses from a set of decoy binding modes in
rigid binding pockets, this method was used in turn to identify near-native binding-site
geometries with respect to residue side-chain orientations towards the ligand(s).
3.1.6 Step 4: Optimising and refining the homology models
To optimise the modelled binding-sites, a strategy of combining good solutions on a
per-residue basis from different homology models is pursued. In the case of identical
main-chain orientations, the most appropriate side-chain rotamers are assembled from
the different models. As the ligand(s) have been placed in the previous modelling
step, the DrugScore rankings between ligand atoms and individual side-chain rotamers
are used to select the most appropriate solution from the set of generated protein
side-chain orientations. In this context, the number of side-chain conformers for each
residue is reduced by performing a complete linkage clustering, merging two conformers
within a user-defined threshold (by default 1.0 A˚). Then the conformer with the best
DrugScore value is selected as cluster representative and the with unfavourable rankings
are eliminated. Finally, all combinations between the remaining cluster representatives
are generated. Solutions that produce intramolecular clashes are discarded. The total
DrugScore scores of the combined pockets are obtained by summing up the individual
scores of the considered side-chain conformers. Finally, the model with the best total
DrugScore values is chosen.
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Since DrugScore pair-potentials implemented into MODELLER consider directionality
of interactions only implicitly, a subsequent structural optimisation using the MAB
force-field in MOLOC is performed. This force-field handles H-bonds using explicit
angular dependencies [Gerber, 1998; Gerber & Mu¨ller, 1995]. In addition, this step
finally removes strained interactions within the binding-site residues.
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3.2 Results and Discussion
The following sections will demonstrate that the MOBILE approach produces more
reliable homology modelled complexes if ligand information is included in this pro-
cess. Subsequently, two ”real life” applications will be given to assess the scope and
demonstrate the power of this method.
3.2.1 Analysis of the generated binding-site models
Comparison of binding-site models generated with and without ligand
information
To assess the influence of ligand information on the protein modelling step, root mean-
square deviations (rmsd) of the modelled binding-site residues with respect to orien-
tations found in reference crystal structures were evaluated for the test data set (46
protein-ligand complexes, see 3.4.1 and Table 3.5). Models were generated (1) with-
out ligand information and (2) considering ligands in terms of the DrugScore pair
potentials. For each of the 46 test set proteins, 10 models were generated with new
side-chain and backbone orientations. Of these, the one with the lowest rmsd with re-
spect to the crystal structure was selected, and an average rmsd considering all atoms
of all binding-site residues was computed. It amounts to 1.90 A˚ if ligand information
was considered (strategy 2) and increases to 2.08 A˚ if no ligand information has been
used (strategy 1). A paired t-test [Zar, 1999] indicates (with a significance of 0.01)
that these mean values are significantly different. With respect to the average rmsds
of each of the 46 binding pockets, in 28 cases better models were obtained considering
the ligand in terms of DrugScore potentials (see Fig. 3.1). In 17 cases better models
were generated neglecting the ligand. In one case a model of equal quality (with re-
spect to rmsd) was obtained. According to the paired t-test, the respective 46 mean
rmsd values show a significance level of 0.1 in favour of the ligand-supported models.
Remarkably, when the ligand is considered in terms of van-der-Waals potentials only,
the resulting binding-site models are even worse (in terms of rmsd values) than those
generated neglecting ligand information. The mean rmsd value over all atoms from all
binding-sites amounts to 2.34 A˚ if the ligand is considered in terms of van-der-Waals
potentials. A possible explanation for this different performance might be attributed
to the significant difference in the steepness of the DrugScore versus van-der-Waals po-
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tentials. Soft potentials are more tolerant with respect to slight structural deficiencies
that generally occur with model-built structures.
Figure 3.1: The differences between rmsd values exhibited by binding-site models
(including side-chain and main-chain atoms) generated with ligand infor-
mation (+ligand) and without ligand information (-ligand).
Fig. 3.2 illustrates the benefit of including ligand information into the protein modelling
process. Here, the orientations of all 11 binding-site residues of glycosidase complexed
with adenine (1aha) were predicted either neglecting (Fig. 3.2a,b) or considering (Fig.
3.2c,d) ligand information. Regarding all binding-site residues, the best of the 10 gen-
erated models showed an overall rmsd value of 1.25 A˚ (neglecting ligand information)
and 0.8 A˚ (considering ligand information), respectively.
Even for the model which was generated without regarding the ligand, the overall
rmsd value is rather satisfying. With 1.25 A˚ it is even better than the average value
found for all 46 test set complexes including ligand information (1.90 A˚). However,
three modelled residues (Tyr70, Tyr111, Ile155, see Fig. 3.2) will clash with a bound
ligand if it is inserted in its crystallographically determined orientation. Besides vi-
sual inspection, the obtained DrugScore rankings potentially indicate the quality of
the generated binding-site models. While the complex generated considering ligand
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Figure 3.2: Binding site of glycosidase complexed with adenine (1aha). The residue
orientation taken from the crystal structure (atom type coded colouring) and those gen-
erated by homology modelling (cyan or yellow) are shown (a) neglecting ligand infor-
mation and (c) including ligand information. Figures (b) and (d) depict the molecular
surfaces of the binding-site residues in their modelled orientation. The bound adenine
has been considered in its orientation as found in the crystal structure. For clarity,
only the binding-site residues are shown in (a) and (c).
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information scores only slightly worse than the native complex, the model generated
neglecting ligand information exhibits a strongly unfavourable score.
Assessing the side-chain prediction accuracy of MODELLER
To assess MODELLER’s power to correctly predict side-chain orientations in protein
binding-sites, again, homology models for all members of the 46 test suite were gen-
erated. Deviating from the previous test, now 100 models (to sample search space
more exhaustively) were generated considering only the side-chain orientations of the
binding-site residues (thus keeping their backbone coordinates fixed). The orientations
of all binding-site side-chains were generated simultaneously. Ligand information was
(1) included in terms of the DrugScore potentials, (2) included in terms of van-der-
Waals potentials and (3) fully ignored. The quality of the protein models was validated
in two ways: (1) the computed binding-site models were considered in total and (2) for
each single residue, only that conformer which had the lowest rmsd compared to the
crystal structure was considered.
The results are summarised in Table 3.1. Regarding the modelled binding pockets in
total, the best solutions are obtained while including the ligand in terms of DrugScore
potentials (1.74 A˚ rmsd). Paired t-tests [Zar, 1999] indicate that this mean value
significantly differs (with a significance level of 0.05) from the mean values which are
obtained when neglecting ligand information (1.82 A˚ rmsd) or including it in terms
of van-der-Waals potentials (1.88 A˚ rmsd). Considering the best conformer of each
predicted side-chain, all three approaches (ligand included in terms of (1) DrugScore
potentials, (2) van-der-Waals potentials, (3) ignored) seem to generate equally good
results (mean rmsd values of 1.04, 1.06, and 1.03 A˚). This is probably due to the
fact that the conformational space of a residue is exhaustively screened by 100 probe
conformers, irrespective whether a ligand is present or not.
Comparing the rms deviations for each of the 46 modelled binding pockets in turn,
in 30 cases better models were obtained when considering the ligand in terms of the
DrugScore potentials (see Fig. 3.3). In 14 cases models with a lower rmsd were ob-
tained when neglecting the ligand, and in two cases models with equal rmsds were
generated. According to the paired t-test, the respective mean rmsd values are signifi-
cantly different (with a significance level of 0.1).
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Figure 3.3: The differences between rmsd values observed for binding-site models
(including only side-chain atoms) generated with ligand information (+lig-
and) and without ligand information (-ligand).
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Table 3.1: Results for predicting side-chains located in the active sites of the test set proteins
active site
predictions with DrugScore potentials
MIN a) 1.74
BEST b) 1.04
predictions with VDW potentials
MIN 1.88
BEST 1.06
predictions without ligand information
MIN 1.82
BEST 1.03
Side-chain predictions were performed for all binding-site
residues of the test data set (Table 3.5) simultaneously,
keeping the ligand and the remaining part of the protein
fixed. In each case, the rmsd is calculated for all atoms in
the given category (i.e. no averaging over residues or
structures).
a) The MIN values consider the binding pockets as whole
entities. For each protein, the binding pocket with the
rmsd value closest to the crystal structure was considered.
b) The BEST values consider the best side-chain conformer
for each single residue of the generated binding site models
compared to the residue in the crystal structure.
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Table 3.2.1 gives a detailed list of the deviations of the multiple binding-site models
generated in the presence of ligand information (in terms of DrugScore potentials).
MODELLER computed geometries with rmsd < 2.0 A˚ in 32 of 46 cases. Obviously,
the prediction accuracy does not depend on the number of residues to be modelled
but rather on the type of residues for which conformations have to be generated. If
a binding pocket contains rigid, space-filling amino acids (in particular Phe, Tyr, Trp
or His), remarkably large deviations are modelled compared to the crystal structure:
Among the 32 satisfactorily modelled pockets, on the average 2.8 Phe, Tyr, Trp or His
residues are present, whereas the 14 cases with rmsd < 2.0 A˚ comprise 5.8 residues
of this type. This is probably due to the fact that an incorrect geometry of a bulky
residue also provokes incorrect geometries of adjacent residues. This influence increases
with a growing number of bulky residues in an active site.
Identification of the best binding-site models
The above-described homology models generated to assess the prediction accuracy of
MODELLER were subsequently used to evaluate DrugScore’s ability to identify near-
native complex geometries (”near-native” requires an rmsd < 2.0 A˚ over all binding-site
residues with respect to the corresponding crystal structure).
For each of the 46 test cases, DrugScore rankings were calculated for the crystal struc-
ture and the 100 model-built complexes. The crystal structures, assumed to represent
the global optimum, should obtain the best score. In fact, DrugScore was able to re-
trieve the crystal structures on rank 1 in 32 out of 46 cases (70 %). Data in Tables 3.2.1
and 3.3 indicate good correlation between DrugScore ranks and deviations of model-
built vs. crystallographically determined binding-sites. If a near-native geometry (<
2.0 A˚) was generated by MODELLER (32 cases), DrugScore was also able to identify
a pose with rmsd < 2.0 A˚ on rank 1 in 21 cases (66 %).
Combination of side-chain conformers in carboxypeptidase A
Even in the overall best model, MODELLER does not necessarily generate the best
possible orientation for all binding-site residues. Thus, an improved model can be
obtained by combining conformers from different models. Fig. 3.4a shows the crys-
tallographically determined binding-site of carboxypeptidase A complexed with L-
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Table 3.2: Results for binding-site models of 46 protein-ligand complexes generated by MOD-
ELLER and scored with DrugScore
pdb
code
rmsd of 1st
DS (A˚) a)
best rmsd
value (A˚) b)
residues in the binding-site c)
≤1.0 A˚
1ABF 0.23 0.13 KQEWFCDDMTRMNN
1LAH 0.96 0.96 DYFSSLSRLSTQD
≤1.5 A˚
1LNA 1.02 1.02 NNAFLVHEILRH
1IMB 1.13 0.90 EDIDGTEGSGTAYEID
1HSL 1.15 1.15 YLSSLSRLGTTQD
1F3E 1.17 0.98 DYDCIQGGLAVMG
121P 1.18 1.18 AGGVGKSAFVDEDPTTAGNKDLSAK
1MLD 1.32 1.32 IRRINLRHGTVSAM
1BLH 1.41 1.28 ASKYSNEINGQAI
≤2.0 A˚
1LMO 1.50 1.05 DQINYWVDNAW
1PPL 1.52 1.52 EENDGSSYGDSQFLFIDGTTLLYLFI
1PSO 1.66 1.42 MEVDGSTYGTFFIIYDGTSLQMLI
1BUG 1.71 1.21 HHFHHIHMGNFAFH
1HDC 1.72 1.63 STGMSLLTYPGMTMTTW
1APT 1.75 1.49 ENDGYGDSFLFIDGTTLLYLFI
1POC 1.85 1.69 IYWCGHGCHDHTLFFVMYI
1CTR 1.87 1.09 EFILEMEAVMA
1AHA 1.89 1.27 VYIFGNYIAER
1HEF 1.89 1.25 RDGADDVIGGIPVI
1ABE 1.96 1.96 KQEWFDDMLTRMNN
1ROB 1.97 1.39 QHKVNTDRHFDAS
≤2.5 A˚
1MRG 2.05 1.41 IYIFGDYIAER
1BYB 2.21 2.21 MLDWIHNVDAERYQWFKSGHW
TCMEALLR
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pdb
code
rmsd of 1st
DS (A˚) a)
best rmsd
value (A˚) b)
residues in the binding-site c)
1EPB 2.21 1.81 FIFWMVLAFKVVAIIKY
1ICN 2.21 2.20 YFMMIKFVFFYLADLWFLQQY
1STP 2.24 1.57 NLSYSVGNWASTWWLD
1TLP 2.25 1.88 YNNAFWFLVHEHYELRDH
1ATL 2.26 1.32 EETLGTHEHHCIRPGL
1RDS 2.27 2.13 YHEYHDYEEPGARHGDDF
1CPS 2.32 1.79 HRERNRHSYLIIYAGTEF
1ELA 2.34 1.85 HTVAWTGCQGDSTSFVSR
1TMN 2.34 1.98 YNNAFFLVHEHYEILRH
1HYT 2.36 2.16 NAFFLVHEHYEIGLRH
1RBP 2.42 1.65 LFLAFATAVLMVGMYLQHYFF
1RNT 2.43 2.43 NYHKYNNYEERHNNF
1AZM 2.46 2.42 FHHEHLLVSLTHW
>2.5 A˚
1SRJ 2.54 2.54 NLSYSAVGNAYWASTWWLD
1BBP 2.55 2.09 ENVEGWANYHYFIHLYNFYKFWL
1DIE 2.62 2.62 WHTTFVWEEHDD
1DID 2.64 2.48 WHMTFVWENEHDHD
1SNC 2.66 2.10 DTRLLDEDKYRLYY
1CBX 2.76 1.49 HERNRHSLIIYAGTE
1HFC 2.89 1.62 GNLAHYVHEHHYPSY
1CIL 3.15 2.94 WNHQHHEHVFVLVSLTTPPW
1MRK 3.26 2.22 YIMFEGNYIEREW
1ACJ 3.31 2.85 GWGGYEFYWIHGY
The rmsd values are calculated for all atoms of each model (i.e. no averaging over
structures). The models are treated as whole entities (i.e. no further optimisation
by combining fragments from different models).
Rigid, space-filling amino acids (Phe, Tyr, Trp, His) are coloured red.
a) rmsd of the binding-site model found on rank 1 by DrugScore, with respect to
the crystal structure.
b) rmsd of the binding-site model with the least deviation from the crystal
structure.
c) residues in the active site (given as one-letter code) for which new geometries
were computed.
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Table 3.3: Results for scoring multiple solutions of 46 protein-ligand complexes generated by
MODELLER
% of complexes with solutions exhibiting
rmsd of the crystal structure
< 1.0 A˚ < 1.5 A˚ < 2.0 A˚ ≥2.0 A˚
All ranks a) 9 43 70 30
1st rank b) 44 47 66 34
a) All solutions of each modelling experiment for the test data set
(Table 3.5) are considered. The number expresses the portion of
all complexes for which at least one solution with the given rmsd
value was computed by MODELLER.
b) Only the binding-site geometry scored to be on the first rank
by DrugScore is considered. The numbers are related to the ones
in the first line.
benzylsuccinate together with 100 generated models (yellow). The three best-scored
models (DrugScore) are shown in Fig. 3.4b. Each individual model contains at least
one residue rotamer that differs significantly from the crystal structure. In contrast,
a combination of rotamers considering only the individually best-scored ones retrieved
from the entire ensemble matches the crystal structure to a greater extent (Fig. 3.4c).
To assess whether the thus generated binding pocket is capable to reproduce a correct
ligand pose, we flexibly docked the ligand present in 1cbx into either the crystal struc-
ture or into the model. Prior to this, the modelled binding pocket was minimised with
MOLOC in presence of the ligand. Of course, this procedure does not correspond to a
realistic scenario in real-life modelling case studies because the modelling process was
restrained with the ligand in its orientation known from the crystal structure, which
will usually not be given. The Lamarckian genetic algorithm was applied in AutoDock
using DrugScore grids to describe the protein binding-sites (Fig. 3.4d) [Sotriffer et al.,
2002b] and ten independent runs were performed. In both cases, docking produced two
different ligand placements (AutoDock scoring energies for crystal structures: -8.03 and
-7.62 kcal/mol and model-built complex: -8.39 and -8.10 kcal/mol, respectively). In
case of the experimentally protein structure, the first solution has an rmsd of 1.21 A˚
with respect to the crystal coordinates. For the model, the second solution deviates
from the crystal coordinates by 0.75 A˚ rmsd. The close energy ranks and the small
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rmsds indicate high similarity between the model and the original crystal structure.
The ligand orientation, albeit found on rank 2, could be reproduced satisfactorily via
docking into the generated model. This convincing result stimulated us to embark on
some real-life modelling applications.
Figure 3.4: Binding site residues of carboxypeptidase A complexed with L-
benzylsuccinate (1cbx). (a) shows the crystal structure (atom type coded colouring)
together with an ensemble of 100 models (yellow). The ligand in its orientation as found
in the crystal structure is coloured in red; (b) depicts the 3 models which obtained the
best DrugScore values (green > cyan > yellow). The model which results as best combi-
nation of all binding-site residues retrieved individually from the generated 100 models
is depicted in violet (c). The best docking solution obtained for the ligand based on the
combined and subsequently minimised model is shown in (d). (Orientation of docked
ligand in yellow, crystallographically determined orientation in red)
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3.2.2 Modelling case studies
Modelling factor Xa based on trypsin
In the previous test examples entire binding pockets have been modelled. Furthermore,
the modelling process was restrained by the ligand in its orientation known from the
crystal structure. In real-life applications, the protein to be modelled may differ by
only several mutations with respect to the template protein(s) and the ligand geometry
might not be exactly known beforehand. To apply such a scenario, homology models of
factor Xa were generated using bovine trypsin as template. Both proteins are members
of the class of trypsin-like serine proteases and share 38 % sequence identity in common
(see Fig. 3.5a). They are known to bind the ligand RPR128515 in a similar orientation
[Maignan et al., 2000]. A sequence alignment was produced by MALIGN3D [Sali &
Blundell, 1990]. In order to mimic a scenario where a ligand orientation is not given
by crystallography, we generated 10 preliminary homology factor Xa models based
on the crystal structure of trypsin (1f0u) excluding ligand information. The ligand
RPR128515 was then flexibly docked into the merged binding pockets using AutoDock.
The docking solutions, together with the ensemble of all modelled residues known to
be crucial for the ligand binding, are depicted in Fig. 3.5b. Nine deviating docking
solutions were obtained. The best solution (rmsd = 0.97 A˚ with respect to the ligand
orientation in the crystal structure 1ezq) is found on rank six (AutoDock energy score:
-14.35 kcal/mol). While the solution found on rank 1 (with an energy score of -14.80
kcal/mol) deviates by 3.33 A˚ rmsd, four additional solutions were generated with an
rmsd value < 2.0 A˚. The solution found on rank 2 differs by 1.64 A˚ from the crystal
coordinates and has an energy score of -14.27 kcal/mol. As indicated in Fig. 3.5b, the
orientations of some modelled binding-site residues (mainly those which are mutated
compared to the original binding pocket of trypsin) are distributed over a large area.
Nevertheless, the mapped configuration space for ligand orientations is rather restricted
since all generated solutions cluster about the native orientation.
Following the strategy outlined above, subsequently new factor Xa models were gen-
erated explicitly considering ligand information. RPR128515 (see Fig. 3.5a)[Maignan
et al., 2000] was included as additional restraint in the protein modelling process. Tak-
ing the crystal structure of bovine trypsin (1f0u)[Maignan et al., 2000] with the ligand
in its co-crystallised orientation as template, 100 new factor Xa models were generated
(Fig. 3.5c). Again, side-chain conformational space is considerably mapped, however,
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Figure 3.5: Superimposed crystal structures of trypsin (beige) and factor Xa
(grey), both complexed with the ligand RPR128515 (a). In (b), the ensem-
ble of relevant binding-site residues of factor Xa (modelled without considering ligand
information using trypsin as template), together with the backbone of the crystal struc-
ture of factor Xa is shown. The ligand is depicted in yellow (native orientation known
from the crystal structure) and red (solutions from docking into the ensemble of the
homology models). Part (c) shows 100 new homology models of factor Xa that were
generated based on trypsin regarding the ligand during the modelling process. The
finally optimised binding-site model (generated by combining side-chains from different
models) is shown in beige in (d), together with structures of factor Xa crystallised with
RPR128515 (1ezq, grey) or with other ligands (cyan).
solutions penetrating into the ligand hardly occur. A final factor Xa model was ob-
tained by combining rotamers retrieved from different homology models (Fig. 3.5d)
(beige). For comparison, the crystal structure of factor Xa with bound RPR128515
(1ezq, cyan) and nine other crystal structures of factor Xa crystallised with different
ligands (grey) are also shown [Maignan et al., 2000; Nar et al., 2001; Guertin et al.,
2002; Kamata et al., 1998; Adler et al., 2000; Brandstetter et al., 1996]. Although the
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rmsd between final model and crystal structure (1ezq) amounts to 1.66 A˚, the features
primarily responsible for binding are well reproduced, apart from Glu147, Gln192 and
Glu97 which do not perfectly align with the crystal structure. In case of Glu147, this
is due to the fact that the backbones of factor Xa and trypsin do not align in this
area. However, as there is no specific interaction between the ligand and Glu147, this
deviation is of no relevance. The ester group of the ligand forms an H-bond to Gln192-
NH. Since the backbone traces match well in the template and the model, deviations in
side-chain orientation of Gln192 are not important for the ligand pose. The same holds
for Glu97, which establishes a strong H-bond (2.5 A˚) through its backbone carbonyl
oxygen and an amino group of the ligand. The other residues, in particular Tyr99 and
Phe174 which contribute to binding (among others) and determine the specificity of the
S4 pocket in factor Xa [Adler et al., 2000], are almost perfectly modelled. Regarding the
fact that some of the discussed binding-site residues in factor Xa exhibit considerable
side-chain flexibility upon binding of different ligands as indicated by multiple structure
determinations (see Fig. 3.5d), the generated model appears rather convincing.
To assess whether the generated binding-site model could be used successfully for vir-
tual screening, we tried to reproduce the binding mode of ten ligands which have been
co-crystallised with factor Xa [Maignan et al., 2000; Nar et al., 2001; Guertin et al.,
2002; Kamata et al., 1998; Adler et al., 2000; Brandstetter et al., 1996]. For reasons of
comparison, we also docked these ligands into the binding pocket of a crystallographi-
cally determined factor Xa structure (1ezq).
The results with respect to rmsd and AutoDock energy score are listed in Table 3.4. The
overall success rate is slightly higher while docking into the factor Xa crystal structure.
Considering the solutions with the lowest rmsd value with respect to the experimental
structure, in 6 (out of 10) cases a better solution is obtained while docking into the
crystal structure instead of our model. However, the differences expressed in terms of
rmsd are not large, in particular, taking the grid approximation within AutoDock and
positional uncertainties in the experimentally determined structures into consideration.
Also, the differences in energy scores are negligible. Only in 2 cases, they amount
to more than 0.5 kcal/mol. Remarkably, docking RPR128515 either back into our
model (rmsd: 0.33 A˚, score: -17.24 kcal/mol) or into the crystal structure (rmsd:
0.78 A˚, score: -16.17 kcal/mol) reveals a better result for the model. This shows, not
unexpectedly, that the model is slightly tailored towards the ligand used to restrain
the modelling. Nevertheless, since convincing results are obtained for all considered
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Table 3.4: Statistics on the docking experiment on factor Xa
Crystal structure a) Model b)
ligand pdb code c) rmsd (A˚) energy (kcal/mol) rmsd (A˚) energy (kcal/mol)
1EZQ 0.78 -16.17 0.33 -17.24
1F0R 1.81 -15.08 2.04 -15.35
1F0S 1.15 -13.50 1.75 -13.51
1FAX 1.98 -15.67 1.89 -15.20
1FJS 1.57 -15.48 2.21 -16.35
1G2L 1.96 -15.70 1.95 -15.76
1G2M 1.98 -15.03 1.83 -15.40
1KSN 1.03 -15.99 1.28 -16.32
1XKA 1.88 -14.71 2.38 -15.12
1XKB 1.90 -14.27 2.53 -14.30
All values refer to the least deviating solution with respect to the crystal structure.
a) Results for docking the ligands into the crystal structure of factor Xa (1ezq).
b) Results for docking the ligands into the homology model of factor Xa.
c) Data set of 10 factor Xa ligands.
ligands, the generated model appears to be well suited for structure-based drug design
purposes.
Modelling aldose reductase based on aldehyde reductase
The previous case study demonstrated that our approach generates sufficiently accu-
rate geometries of protein residues to establish specific interactions with ligands. In
the following example, we will investigate how well binding modes can be reproduced
for a protein known from crystal structure analysis to exhibit pronounced induced-fit
adaptations upon ligand binding.
Aldose reductase (AR), an NADPH-dependent enzyme, catalyses the reduction of glu-
cose along the sorbitol pathway, and, therefore, represents a promising drug target in
diabetes therapy of secondary complication.
AR shares 49.5 % sequence identity with aldehyde reductase. In particular, the co-
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Figure 3.6: Superimposed crystal structures of aldose reductase (AR, cyan) and
aldehyde reductase (marine) with the NADP+ cofactor (shown in beige)
in its orientation from aldehyde reductase. The loop regions composing the
specificity pockets are coloured yellow (AR) and red (aldehyde reductase), respectively.
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factor binding-sites and the regions where the hydrid transfer from NADPH to the
carbonyl carbon of the substrates occur (anion binding pocket), are structurally highly
conserved (see Fig. 3.6). However, aldehyde reductase exhibits an additional loop,
comprising 11 residues, that is responsible for differences in substrate specificity. Inter-
estingly, in AR, this segment, is composed of only 4 residues (Ala299-Ser302). Here, it
is part of the hydrophobic specificity pocket and shows the most striking adaptations
upon ligand binding. An MD simulation performed on the ultra-high resolution crys-
tal structure of human aldose reductase complexed with IDD59497 revealed the most
pronounced flexibility in this region with the largest side-chain mobility exhibited by
Leu300.[Sotriffer et al., 2003] A very distinct binding-site conformation (compared to
the IDD594 complex) is observed for tolrestat binding (1ah3) to the porcine enzyme.
Superimposition with the IDD594 complex (Fig. 3.7) reveals identical orientations of
the ligand’s carboxylates in the anion binding pocket, whereas tolrestat would clash
into Leu300 in the IDD594 structure.
To examine whether these specific binding-site geometries could be modelled by the
MOBILE approach, two different sets of AR models were generated including either
tolrestat (1ah0) or IDD594 as ligand-derived restraints. According to our strategy,
we initially generated 100 preliminary AR models based on the crystal structure of
aldehyde reductase (1hqt) neglecting ligand information. The coordinates of the co-
factor (being identical in AR and aldehyde reductase) were transferred from aldehyde
reductase to the AR models. Next, we placed tolrestat and IDD594 into the ensemble
of preliminary homology models using AutoDock. In case of tolrestat, a good docking
solution (2.05 A˚ rmsd) was found on rank 2. For the IDD594 complex, a solution
with 2.53 A˚ rmsd was obtained on rank 3. To further refine the modelled complexes,
we performed an additional iteration of our approach. Therefore, the obtained ligand
orientations of tolrestat and IDD594 were used to restrain the subsequent homology
modelling. Considering each of the docked inhibitors separately, two sets of 100 ho-
mology models based on aldehyde reductase (1hqt) as template were generated. Next,
we docked the two ligands into the ensembles of the produced protein models. For
tolrestat, a solution with 0.84 A˚ rmsd with respect to the orientation observed in the
crystal structure was obtained (found on rank 3), the best solution for IDD594 had 1.22
A˚ rmsd (also on rank 3). Compared to the respective rms deviations for the docking
into the preliminary homology models (as shown above: 2.05 A˚ (tolrestat) and 2.53
A˚ (IDD594)), these improvements for the docking into the refined models are strongly
significant.
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Figure 3.7: Conformational changes in the AR binding pocket in consequence of
inhibitor binding. The nicotinamide ring of the cofactor is shown in red. In blue,
the orientations of tolrestat and the side chains of Leu300 are displayed (as observed in
the corresponding crystal structure 1ah3), the latter residue is mainly affected by the
conformational rearrangement of the binding pocket upon ligand binding. The ligand
IDD594, together with the obtained geometry of the corresponding binding-site residue,
is depicted in orange.
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Besides producing a near-native ligand geometry, the prime interest is focused on pre-
diction of a correct loop geometry since the remaining part of the binding pockets in
AR and aldehyde reductase are rather similar. Accordingly, we scored only the inter-
actions formed between both docked ligands and the residues in the sequence stretch
Ala299-Ser302 of the generated models using DrugScore. For both cases, loop geome-
tries closely approximating the crystal structures (a comparison is shown in Fig. 3.8a
and 3.8b) were found among the top-scored solutions. In case of tolrestat, the most
convincing loop orientation was found on rank 2 (rmsd considering the side-chain atoms
of Leu300: 1.22 A˚), for IDD594 the loop conformer on rank 2 deviates by 1.49 A˚.
Figure 3.8: Superimposition of the crystal structures (blue) and the modelled
complexes (cyan) of AR with (a) tolrestat and (b) IDD594. The side-chain
orientations of Leu300 are indicated. The nicotinamide ring of the cofactor is shown in
red.
AR provides an example for ligand-induced protein-adaptations affecting even the back-
bone conformation. This case study demonstrates that realistic protein-ligand geome-
tries can be generated by applying the MOBILE approach to this rather complex sys-
tem, where ligands reinforce different loop conformations upon binding. Furthermore,
we have shown that the mutual orientations between the protein and a particular ligand
can be adjusted in a stepwise fashion. Even though the initial starting protein-ligand
geometries deviated considerably from the orientations found in the referring crystal
structures, near-native geometries could be generated for both, the tolrestat- and the
IDD594-complex after performing a second cycle of the MOBILE approach.
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In this contribution, a novel strategy (MOBILE) is presented to consider informa-
tion about the binding mode of bioactive ligands during the homology modelling pro-
cess. It starts with a combined set of homology models, and ligands are placed into
a crude binding-site representation via docking onto averaged property fields derived
from knowledge-based potentials. Once the ligands are placed, a new set of homol-
ogy models is generated. However, in this step, ligand information is considered as
additional restraint in terms of knowledge-based pair potentials. Consulting a large
ensemble of produced models exhibiting different side-chain rotamers for the binding-
site residues, a composite picture is assembled considering the individually best scored
rotamers with respect to the ligand. After a local force-field optimisation, the obtained
binding-site models are used for flexible docking. As a result, protein binding-site mod-
els of higher accuracy and relevance are generated. The application of DrugScore pair
potentials proved efficient to restrain the homology modelling process and to score and
optimise the modelled protein-ligand complexes. This was demonstrated using a test
data set of 46 complexes and further validated by applying the new strategy to relevant
modelling scenarios.
A commonly applied protocol for modelling binding-sites of unknown proteins usually
starts with generating one preliminary homology model of the uncomplexed protein,
occasionally optimised by molecular dynamics. After placing a ligand into the mod-
elled active site, usually the entire complex is subjected to a further refinement. As
pointed out by Schonbrun et al.,[Schonbrun et al., 2002] it is debatable whether a refine-
ment by molecular dynamics actually improves the predicted structure. Indeed, none
of the top comparative modelling groups involved in CASP4[Moult et al., 2001] used
such protocols, probably because previous experience did not suggest any advantage
in predictive power. Most likely this is due to the limited sampling of configuration
space using standard molecular dynamics although this limitation could be overcome
by generalised-ensemble simulations. Accordingly, it is rather unlikely that the global
minimum geometry of a protein-ligand complex can be obtained if the starting ge-
ometry is distant from the near-native one and separated by a high energy barrier.
Supposedly, this limitation does not occur in our approach because the configuration
space of the modelled binding pocket is more exhaustively sampled simultaneously con-
sidering the ligand in a near-native orientation. The global minimum is approximated
as composite picture by identifying optimally scored rotamers from a large set of gen-
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erated models. The individual rotamers are scored with respect to a given ligand pose
using DrugScore. This function has been demonstrated to identify efficiently native
and near-native protein-ligand configurations.[Gohlke et al., 2000a]
Similar to protein-ligand docking, the strategy to detect near-native complex geome-
tries involves two equally important steps: (1) computing relevant geometries and (2)
identifying the pose being most close to the experimentally given situation (scoring).
The program MODELLER used in our approach produces relevant geometries of pro-
tein binding-sites even in the absence of a placed ligand, particularly, if the search space
for side-chain rotamers is small and, thus, can be sampled efficiently. However, our
approach also shows that the efficiency and accuracy of the modelling process is clearly
enhanced by considering ligand information. The second goal - identifying complexes
with near-native geometries - inevitably requires the presence of a ligand in a realistic
orientation.
It has been shown that relevant binding modes can be produced by docking ligands into
ensembles of protein structures.[Claussen et al., 2001] Smoothing the potential energy
surface results in an even faster convergence of the docking problem. Nevertheless, due
to the approximate nature of the binding-site representations derived from an ensemble
of modelled protein geometries, the use of conformationally restricted ligands is advis-
able. If a 3D superposition of ligands, e.g. in the context of a previously performed
3D-QSAR study, is available, these aligned ligands could be docked rigidly into the
homology models. This will further reduce the search space of the docking problem.
The mutual similarity of different ligands in their docked orientations can be used as
an additional criterion to assess the quality of the docking solutions.[Schafferhans &
Klebe, 2001]
In the presented approach, ligand information is only used in structural terms. Addi-
tionally, affinity data of the ligands might be considered to assess the quality of the
generated homology models. Such concepts will result in a ”QSAR-refined homology
modelling”. The first option would be to use a given set of ligands, docked into several
homology models, and the affinity of all resulting complexes is predicted. The model
that yields the best correlation between calculated and experimental affinities is ren-
dered prominent. A possible limitation of this strategy might be that the presently
available scoring functions cannot predict affinities accurately enough. Interestingly,
3D-QSAR models based on superimposed ligands reveal surprisingly high predictive
power in affinity estimation, provided a correct superimposition is given. In conse-
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quence, a second alternative to assess the quality of the produced models would be to
generate multiple QSAR models based on distinct ligand alignments obtained from the
docking into the various homology models. In analogy to the procedure followed by
several authors [Jalaie & Erickson, 2000; Schafferhans & Klebe, 2001; Kim, 1998], the
statistical significance of the generated QSAR models is used to assess the relevance
of the different protein models. A further possibility to reliably predict the affini-
ties between homology models and ligands would be to establish an AFMoC model.
[Gohlke & Klebe, 2002b] AFMoC tailors protein-specifically adopted DrugScore pair-
potentials to one particular protein by considering additional ligand-based information
in a CoMFA-type approach. The statistical significance of an AFMoC model thus ex-
plicitly reflects the quality of the underlying protein model. A further advantage is that
AFMoC allows the user to gradually move from general knowledge-based potentials to
protein-specifically adopted ones, depending on the confidence in the generated protein
model and the amount of ligand data available for training.
To assess the predictive power of protein homology modelling techniques, usually the
rmsd between the model-built and the corresponding crystal structure is determined.
In the present contribution, we follow the same procedure. However, one has to regard
intrinsic accuracy limits. X-ray structures obtained for the same protein in different
laboratories or determined in two different crystal forms can show deviations in main-
chain atoms of about 0.5 A˚ rmsd. The solvent-exposed side-chains can differ by as much
as 1.5 A˚, while for more buried side-chains, the difference can amount to 1.0 A˚ [Levitt
et al., 1997]. Exploring the theoretical prediction limit of commonly applied force-
fields, Petrella et al. suggested a limit for side-chain prediction of 0.8 A˚ [Petrella et al.,
1998]. Xiang et al. assume accuracy limits of 0.7 A˚ for the side-chains of core residues
[Xiang & Honig, 2001]. In light of these estimates, the accuracies achieved by our
approach on the test set for binding-site residues (1.0 A˚) are quite convincing. This
becomes even more pronounced when considering that in the two above-mentioned
studies, all residues were kept fixed except the one being predicted, whereas in our
approach the orientations of all protein side-chains in the active site are predicted
simultaneously. Finally, as noted by Tramontano et al. [Tramontano et al., 2001],
the rmsd criterion is widely accepted, but not necessarily always a perfect figure-of-
merit. Criteria that rank proper side-chain orientations with respect to neighbouring
side-chains would be more conclusive. In particular, this is important while evaluating
the side-chain orientations of a protein with respect to a preoriented ligand. In our
approach, DrugScore convincingly supports in particular this step.
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For proteins exhibiting pronounced induced-fit adaptations, homology modelling based
on a single crystal structure of a related protein is difficult and results could be mis-
leading. Even so crystal structures are our most reliable source to learn about protein
geometry, they only provide a frozen snap-shot of a dynamically fluctuating system.
Local effects such as the applied pH conditions or impacts imposed by crystal packing
do influence binding modes [Stubbs et al., 2002]. Through ligand binding, different
local minima experienced by the uncomplexed protein under dynamic conditions can
be stabilised and observed as favourable binding-site geometries in a crystal [Sotriffer
et al., 2003].
Homology modelling using MODELLER is based on a reference template structure and
the approach tries to carry over as much information as possible from the template into
the model, in particular in regions of high sequence identity and structural conservation.
To perform an exhaustive side-chain screening by our approach, such regions must
be excluded from the direct homology matching step. As an alternative, structural
variability can also be introduced in the modelling process by considering multiple
template structures exhibiting deviating conformations in the flexible regions.
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3.4.1 Test data set
A test data set of 46 protein ligand complexes was compiled to validate the performance
of our approach (see Table 3.5). This set has been extracted from the 91 protein-
ligand complexes used for DrugScore validation [Gohlke et al., 2000a], considering the
following criteria: (1) As MODELLER is primarily intended for homology modelling,
we only selected structures which do not contain cofactors next to the active site. (2)
The only hetero atoms allowed (besides those in the ligands) were metal ions. (3)
We also eliminated all water molecules as their positions will generally not (yet) be
predicted realistically in modelling scenarios. We used this test data set for scaling
the DrugScore potentials to the MODELLER force-field, comparing homology models
generated with and without ligand information, assessing the side-chain prediction
accuracy of MODELLER, and evaluating DrugScore’s power to identify near-native
complex geometries.
Table 3.5: PDB codes of proteins used for the parameterisation of the pair potentials
121P 1ABE 1ABF 1ACJ 1AHA 1APT 1ATL
1AZM 1BBP 1BLH 1BUG 1BYB 1CBX 1CIL
1CPS 1CTR 1DID 1DIE 1ELA 1EPB 1F3E
1HDC 1HEF 1HFC 1HSL 1HYT 1ICN 1IMB
1LAH 1LMO 1LNA 1MLD 1MRG 1MRK 1POC
1PPL 1PSO 1RBP 1RDS 1RNT 1ROB 1SNC
1SRJ 1STP 1TLP 1TMN
3.4.2 Generation of binding-site models of the test data set
For validation studies performed with the test data set (see Table 3.5), only the ge-
ometries of residues next to the active site (within a distance of 4.5 A˚ to the ligand)
were modelled. Here, the crystal structure of the respective PDB entry served itself as
template for the modelling process (Fig. 3.9). The coordinates of all but the binding-
site residues of the protein were kept unchanged with respect to the templates. New
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geometries for binding-site residues (including side-chain and main-chain atoms) were
forced to be generated by MODELLER by keeping the binding-site residues unmatched
in the sequence alignment (see Fig. 3.9, panel C). For the de novo prediction of side-
chain geometries only, the referring residues in the template structures were mutated
to Gly (see Fig. 3.9, panel B).
Figure 3.9: Generation of binding-site models for the proteins of the test set
(Table 3.5). An aligned sequence stretch of a protein is shown in panel A. Five
residues, belonging to the active site, are shaded grey. The procedure for generating
binding-site models works as follows: The available structure of the Template protein
serves as basis to model the structure of the Model sequence. Generating a homology
model with the identically aligned sequences as represented in panel A would result
in a Model structure that is identical to the Template. To generate a Model with new
side-chain orientations of the binding-site residues (while keeping the remaining part
of the protein as in the Template structure), sequence alignment (panel B) is used.
Here, the binding-site residues in the Template structure are mutated to Gly. Thus,
information about the respective side-chain coordinates cannot be inferred by homology
and must be predicted de novo by MODELLER. For modelling the main- and side-
chain orientations of the Model, the binding-site residues are unaligned in the sequence
alignment, thus, leading to a complete neglect of information in MODELLER about
these residues from the Template structure.
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3.4.3 Scaling the DrugScore potentials with respect to the
MODELLER force-field
In order to incorporate the DrugScore pair potentials as additional restraints into the
MODELLER force-field, they were empirically scaled with respect to the remaining
force-field terms. Apart from the terms adapted from CHARMM to constrain stereo-
chemical properties, the MODELLER force-field consists of probability density func-
tions of purely empirical origin. Therefore, it appears justified to weight the DrugScore
potentials empirically. This adjustment was accomplished using our test data set of 46
complexes (see Table 3.5) by systematically varying the contribution of the DrugScore
pair potentials to the MODELLER molecular probability density function. For this
parameterisation study, the coordinates of the ligand atoms were adapted from the
referring PDB entries. For each parameter setting (i.e. scaling factor), 10 homol-
ogy models were generated. In these ”models”, all coordinates apart from residues
within 4.5 A˚ distance to the ligand were kept identical to the crystal coordinates. The
binding-site residues, however, were generated de novo by MODELLER, i.e. without
considering information taken from the template structure. The models generated us-
ing the actual parameter setting were assessed with respect to their spatial deviation
from the corresponding crystal structures by computing the rmsd between the residues
of the modelled and crystallographically determined binding-site. As a further crite-
rion to consider the similarity between model and crystal structure, grids based on
DrugScore potentials were calculated in the modelled and crystallographic binding-
sites and their mutual similarity has been assessed by evaluating the Hodgkin index
[Hodgkin & Richards, 1987]. A scaling factor of 7.5 • 10−5 was finally found as best
solution to adjust the DrugScore potentials to the MODELLER force-field. A similar
scaling factor was obtained by Sotriffer et al. scaling DrugScore to the intramolecular
force-field implemented into AutoDock [Sotriffer et al., 2002b].
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4 Generation and validation of a
ligand-supported homology model of the
neurokinin-1 receptor by virtual
screening for a submicromolar inhibitor
4.1 Biological target system
4.1.1 G-protein-coupled receptors
Introduction
G-protein-coupled receptors (GPCRs) form one of the largest superfamilies of cell-
surface receptors mediating responses to diverse signals, for example, visual, olfacto-
rial, hormonal, and neurotransmitter signals [Marinissen & Gutkind, 2001]. A large
percentage of prescription drugs (30 % of the top 50 sellers in 2001, 50 % of all currently
launched drugs) target one or more GPCRs, with most major therapeutic areas be-
ing served to some extent by several GPCR-based drugs [Scussa, 2002]. Currently,
there are more than 3000 sequences of this family known for different organisms,
and GPCR genes correspond to 3 % of the genes in humans. The superfamily of
GPCRs is subdivided into three main receptor subfamilies on the basis of the phar-
macological nature of their ligands and sequence similarity. The division includes the
class I (rhodopsin like) receptors (their ligands are biogenic amines, neuropeptides,
chemokines and prostanoids), the class II receptors (secretin like) and the class III re-
ceptors (metabotropic glutamate receptor like), which represent about 89 %, 7 % and
4 %, respectively, of the known GPCRs [Menzaghi et al., 2002].
GPCRs play a key role in a whole series of processes in our body, establishing a
functional and unidirectional link between the exterior of a cell and its cytoplasm
[Baldwin, 1994; Nederkoorn et al., 1995; Oliveira et al., 1993; van Rhee & Jacobson,
1996; Selbie & Hill, 1998]. When a ligand interacts with the extracellular half of
the GPCR, a signal is generated which is transmitted through the membrane to the
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Figure 4.1: Family classification of G-protein coupled receptors. From [Chalmers &
Behan, 2002].
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cytosolic side where a G-protein is activated. This G-protein in turn activates one or
more of a variety of secondary messengers. The mediation of the ligand action occurs
through a conformational change of the GPCR [Oliveira et al., 1999; Birnbaumer &
Birnbaumer, 1995]. A simple model suggests that GPCRs exist in an equilibrium of
active and inactive states, R* and R, respectively [Costa & Hertz, 1989; Samama et al.,
1993; Lefkowitz et al., 1993]. Only R* can bind to the G-protein and produce a cellular
response. Under physiological conditions, the ligand-receptor interaction results in an
increase in the ligand bound receptor LR*, resulting in the production of an LR*-G-
protein complex and consequent cellular response.
GPCR Structural Information
It has long been known that GPCRs share a central core domain constituted of seven
transmembrane helices (TM-I through -VII) connected by three intracellular (i1, i2
and i3) and three extracellular (e1, e2 and e3) loops (see Fig. 4.2) [Baldwin, 1993].
Albeit their common structural features, GPCRs do not share any overall sequence
homology [Kolakowski Jr, 1994; Probst et al., 1992]. Significant sequence homology is
found, however, within several subfamilies [Gether, 2000]. Despite the divergent overall
sequence homology of GPCRs, the antagonist binding-site is often located in the same
region where bovine rhodopsin binds the retinal ligand [Bo¨hm et al., 1996]. On the
other hand, it was shown by Jacoby et al. that for the monoamine GPCR 5HT1A three
distinct biding sites exist [Jacoby et al., 1999; Jacoby, 2001]. This was also suggested
for other monoamine GPCRs.
A cartoon diagram of the recently resolved high-resolution structure of rhodopsin [Pal-
czewski et al., 2000; Teller et al., 2001] is depicted in Fig. 4.3. The retinylidene
chromophore (coloured cyan), which is covalently bound to the receptor, is located
more toward the extracellular boundary of the plane of the putative membrane bilayer.
Absorption of a photon by 11-cis-retinal causes its isomerisation to all-trans-retinal,
initiating a conformational change in the receptor that leads to its activation. One of
the most striking features of the structure of rhodopsin is the presence and position-
ing of the β4-hairpin (coloured red in Fig. 4.3) within the second extracellular loop
which holds the chromophore very firmly in place by many contacts. The β4-hairpin
is stabilised by a disulfide bond between Cys110 and Cys187 which is highly conserved
in the family of the GPCRs [Sakmar, 2002]. The role of the E2 loop in rhodopsin
and the other GPCRs is not known and still a question of debate. Experiments in
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Figure 4.2: (A) GPCRs comprise a central common core composed of seven trans-
membrane helices (TM-I to -VII) connected by three intracellular (i1, i2,
i3) and three extracellular (e1, e2, e3) loops. The diversity of messages which
activate these receptors is an illustration for their evolutionary success. (B) Illustra-
tion of the central core of rhodopsin, viewed from the cytoplasm. The core
is represented under its ‘active conformation’. The TM-VI and -VII lean out of the
structure, the TM-VI turn by 30 % on its axis (clockwise as viewed from the cyto-
plasm) [Bourne, 1997]. This opens a cleft in the central core in which G proteins can
find their way. i2 and i3 loops are the two main loops engaged in G-protein recognition
and activation. From [Bockaert & Pin, 1999]
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Figure 4.3: Cartoon representation of the high-resolution X-ray structure of bovine
rhodopsin. The E2 loop which contains the β4-hairpin is coloured red. It is in close
contact to the retinal ligand (coloured cyan).
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the laboratory of Sakmar et al. indicate that its main role might be to regulate the
stability of the active state of the receptor in which the all-trans chromophore acts,
suggesting that the E2 loop in other GPCRs also might provide contacts with agonist
ligands [Sakmar, 2002]. The presence of the β4-hairpin raises the question how the
ligand gets from the external medium into the binding pocket. Oliveira et al. suggest
the following two options [Oliveira et al., 2002]:
1. Through the space between the helices VII, I and II, and the beta turn 182-185
in the IV-V hairpin, through a space flanked by the 178-182 strand, the part of
the IV-V hairpin directly after Cys187, and the helices VI-VII
2. Motion of the IV-V hairpin leaves the entry to the binding cavity open long
enough for a ligand to enter
The authors furthermore note that the β4-hairpin sequence is highly variable among
the family GPCRs. It is therefore unlikely that any function can be found in this area
that is common to many receptors. Accordingly, it is questionable if the β4-hairpin in
the orientation observed in bovine rhodopsin provides a reasonable structural template
for homology models of other GPCRs.
Considering the fact that the global sequence identity between bovine rhodopsin and
other GPCRs is generally below 25 %, might lead to the conclusion that rhodopsin
might not provide a proper template for homology modelling. Normally, when the
sequence identity between the model and the template is below 30 %, the sequence
alignment is the main bottleneck in the modelling procedure. GPCRs form an exception
to this rule [Oliveira et al., 2002]. Each helix contains one or more highly conserved
residues that allow for an unambiguous alignment of the helices of the model and the
bovine rhodopsin template. Therefore, it seems reasonable to assume that the geometry
of the transmembrane region is very similar among GPCRs.
Until the high-resolution X-ray structure of bovine rhodopsin became available [Pal-
czewski et al., 2000; Teller et al., 2001; Okada et al., 2002], inferences about the struc-
ture of GPCRs have been based on cryo-microscopy studies of rhodopsin [Unger &
Schertler, 1995; Schertler & Hargrave, 1995; Davies et al., 1996] and the high-resolution
structures of bacteriorhodopsin [Henderson et al., 1990; Pebay-Peyroula et al., 1997;
Luecke et al., 1999]. Recent pairwise comparisons of the high-resolution structures
of rhodopsin and bacteriorhodopsin show that helices IV and V do not superimpose
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[Teller et al., 2001]. The twists and kinks in the helices create substantial differences
between the two proteins. Furthermore, bacteriorhodopsin, even though it belongs to
the family of 7-TM receptors, does not couple through G-proteins and thus is not a
member of the GPCR family. Before the high-resolution structure of bovine rhodopsin
became available, a common approach for generating hypotheses about binding mech-
anisms was the generation of preliminary GPCR models based on bacteriorhodopsin,
subsequently refined by experimental findings from structure-activity, mutagenesis and
affinity labelling studies [Gershengorn & Osman, 2001]. Although models based on bac-
teriorhodopsin could thus be useful for studying the functional architecture of GPCRs,
they are probably not reliable enough for precise structure-based ligand design.
GPCRs and drug design
Nowadays, the search and optimisation of lead structures for GPCRs predominantly
relies on ligand-based drug design techniques. They usually start by establishing a
pharmacophore model. If only limited information about ligands is available, such a
model can be deduced directly from the natural ligand and its analogues. It can then
be exploited for virtual screening. This technique has been applied successfully for
the search of novel lead structures by researchers at Merck for the sst receptor [Yang
et al., 1998] and Aventis for the urotensin II receptor [Flohr et al., 2002]. If information
about other ligands is available, a common strategy is to spatially superimpose several
structurally diverse, preferably rigid ligands to identify common features responsible
and essential for binding the target receptor. These features are subsequently translated
into a pharmacophore model used for virtual screening (for example, see [Marriott et al.,
1999]). Another new successful strategy for finding novel leads is based on the fact that
many GPCR ligands share common structural motifs, although binding to different
receptors. Based on this observation, so-called targeted libraries for GPCRs have been
compiled [Balakin et al., 2002, 2003]. These libraries are assembled and continuously
enriched by compounds with structural features required to bind to members of the
target family. Indeed, such preselected libraries provide significantly higher hit rates
compared to the screening of randomly selected libraries.
Another conceivable option to discover novel leads for GPCRs would be a docking
screen using a homology model of the target receptor. To our knowledge, such pro-
cedure has not yet been described in literature. This is possibly due to the fact that
the sequence identity among the active sites of bovine rhodopsin and other GPCRs are
68 4.1 Biological target system
often too low to allow for reliable prediction of side-chain geometries at the binding-
sites. Aspects concerning homology modelling of GPCRs for drug design have been
discussed in recent review articles ([Klabunde & Hessler, 2002; Flower, 1999; Balles-
teros et al., 2001; Gether, 2000]). Flower suggests that improvement of GPCR models
for the purpose of structure-based drug design can be achieved by refining preliminary
models using information from mutational data. Prediction accuracy can supposedly
be optimised by combining QSAR with receptor modelling [Flower, 1999].
Indeed, the knowledge about ligands is often combined with is data of GPCRs, which
is increasingly communicated via the internet, e.g. the GPCRDB [Horn et al., 1998],
the GRAP Mutant Database [Beukers et al., 1999; Kristiansen et al., 1996; Edvardsen
& Kristiansen, 1997], and the Olfactory Database [Crasto et al., 2002]. Ligand binding
information on GPCRs and their effectors is available at the PDSP (Psychoactive Drug
Screening Program) database [Roth et al., 2000]. Combining the receptor information
with structure-activity data of ligands, the relevant amino acids and the composite
interacting moieties of the ligands can be identified and, thus, provide a starting point
for further optimisation of binding affinity.
Examples of GPCR models based on the crystal structure of bovine rhodopsin, refined
or validated by ligand and mutational data, can be found in literature (for example
[Jo¨hren & Ho¨ltje, 2002; Chambers & Nichols, 2002; Shim et al., 2003; Lopez-Rodriguez
et al., 2001]). As mentioned above, no such homology model was ever used to screen
for novel compounds, although Bissantz et al. recently demonstrated that homology
models of GPCRs, based on bovine rhodopsin, are reliable enough to be used for
virtual screening of chemical databases [Bissantz et al., 2003]. This was shown by
successful retrieval of known antagonists of the dopamine D3 receptor, the muscarinic
M1 receptor, and the vasopressin V1a receptor via docking from a database, which
additionally included randomly collected drug-like compounds.
An important issue in homology modelling of GPCRs for the purpose of structure-based
drug design is the fact that the bovine rhodopsin structure resolved by Palczewski et al.
is that of the inactive state of rhodopsin. This justifies the usage of bovine rhodopsin
as structural template as long as ligands are searched which preserve the addressed
GPCR in its inactive conformation (i.e., antagonists).
The task of finding agonists for GPCRs represents a more demanding challenge because
in bovine rhodopsin, the activation, i. e. the coupling with the G-protein involves an
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alteration in the relative orientation of TM III and TM VI, with an accompanying
rotation of TM VI (see Fig. 4.2B). These movements probably result in an alteration
in the position of the third intracellular loop (i3), which uncovers residues related
to G-protein coupling [Chalmers & Behan, 2002]. Once the molecular details about
the activation mechanism are resolved, it could be possible to transfer these steps
to other GPCRs, assuming that the activation process is similar among all GPCRs
[Oliveira et al., 2002]. However, considering the divergence of the extracellular loops
which interact with the natural ligands and taking into account the diversity of these
ligands in terms of molecular size and chemical diversity, it is in question whether all
GPCRs follow exactly the same activation mechanism, or whether the coupling with
the G-protein can be achieved by slightly different structural rearrangements. In any
case, as long as the molecular mechanism of activation at an atomic resolution is still
unresolved, it is probably unreasonable to search for agonists based on such a homology
model. Consequently, ligand-based drug design is probably a more promising strategy
to discover new agonists for GPCRs. This assumption is supported by the docking
results revealed by Bissantz et al., who successfully identified GPCR antagonists from
large compound databases via docking, but the models were not accurate enough for
retrieving known agonists [Bissantz et al., 2003].
Homology Modelling of GPCRs
Due to the enormous importance of GPCRs as drug targets and to support structure-
based drug design, several approaches have been developed especially with respect to
the modelling of GPCRs.
• Shacham et al. presented a technology, named PREDICT, which models the 3D
structure of any GPCR based on its amino acid sequence, without the use of
a structural template [Shacham et al., 2001]. The modelling procedure reveals
a low-energy conformation by optimising a model considering a large number
of properties, including helical-packing geometry, multihelical tilts, helix orien-
tations, sidechain rotamers, helix membrane-surface crossing, and helical kinks.
The huge size of the protein conformational space is covered through a hier-
archical design, starting with a coarse representation and gradually increasing
its complexity until reaching a full atomistic model. PREDICT was capable of
reproducing the experimental structure of bovine rhodopsin.
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Furthermore, PREDICT has been incorporated into the Predix Drug Discovery
Platform [Predix]. Within this platform, PREDICT-generated models of GPCRs
have been used for computational screening of virtual molecular libraries. Using
these models, the authors report hit rates of 85 to 100 % when screening for known
binders and hit rates of 10 to 24 % for unknown binders (with an experimental
binding affinity of < 5 µM) [Becker et al., 2003]. To the best of our knowledge,
GPCR models generated by PREDICT are the only ones reported to yield novel
GPCR binders identified by docking.
• Another method for predicting the structure of GPCRs (MembStruk), and the
binding mode of ligands classified in terms of relative binding affinities (HierDock)
was developed by Vaidehi et al. [Vaidehi et al., 2002]. Similar to PREDICT,
MembStruk predicts 3D structures by using only the amino acid sequence of the
target GPCR by applying a hierarchical modelling strategy. Starting with the
prediction of the TM regions, the individual helices are constructed and oriented
according to the 7.5 A˚ electron density map of bovine rhodopsin. After a coarse
grain optimisation of the TM bundle, interhelical loops are added and the full
structure is generated.
The HierDock ligand screening protocol also follows a hierarchical strategy to
examine ligand binding conformations and calculating their binding energies.
MembStruk and HierDock were successfully used for predicting the retinal-bound
structure of bovine rhodopsin and applied to the β1-adrenergic receptor, endothe-
lial differential gene 6, mouse and rat l7 olfactory receptors, and the human sweet
receptor.
• An integrated GPCR modelling approach was introduced by Mu¨ller [Mu¨ller,
2000]. Based on a sequence alignment established by exhaustive sequence simi-
larity searches over all sequence databases, an in-plane projection structure for
the seven transmembrane helices is derived assisted by calculated vectorial prop-
erty moments. After mapping this 2D topology representation onto the Cα-trace
suggested by Baldwin [Baldwin et al., 1997], side-chains are added in favourable
conformation. Such models are refined by molecular dynamics simulation under
explicit consideration of the non-isotropic environment for energetic relaxation.
This procedure was applied to the human CCK-B receptor, followed by docking
studies of nonpeptide antagonists utilising the DragHome concept introduced in
section 2.2.1 [Escherich et al., 2001].
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• Another program for building the transmembrane domains of GPCRs is BUNDLE
[Filizola et al., 1998]. The following steps are involved in the construction of a
GPCR model: After identifying the helices, their centres are arranged according
to the low-electron density map of rhodopsin, followed by the computation of the
tilt of each helix. After defining a local coordinate axis for each of the helices,
they are oriented in an antiparallel fashion and rotated along their axes. In the
next step, each helix is rotated along an axis perpendicular to the helical one;
finally, each helix is translated to its centre deduced from the projection map.
The described procedure was used to model rhodopsin and other GPCRs. At the
time of publication, the low resolution crystal structure of bovine rhodopsin was
not available, thus a detailed validation of generated models was not possible.
4.1.2 The Neurokinin Receptors
The tachykinins are a family of neuropeptides comprising substance P, neurokinin A
and neurokinin B, which share the C-terminal sequence Phe-X-Gly-Leu-Met-NH2 in
common. The preferred receptors for these neuropeptides are named (respectively)
neurokinin-1 (NK1), neurokinin-2 (NK2), and neurokinin-3 (NK3) (see Table 4.1).
They belong to the family of the GPCRs and share a high sequence homology. For
example, the human (h)NK3 receptor sequence has 74 % and 68 % homology with the
hNK1 and hNK2 receptors, respectively, with maximal sequence conservation in the pu-
tative transmembrane regions and minimal identity at the amino- and carboxy-termini.
Whereas NK1 and NK2 are widely distributed in the central nervous system (CNS)
and peripheral tissue, NK3 seems to be stronger localised in the CNS. Tachykinins have
been described to be implicated in numerous physiological and pathological processes
such as neuronal modulation, plasma protein extravasation, mast cell degranulation,
stimulation of mucus secretion, or neurotropic and mitogenic effects. Modulation of
their functional properties is suggested for the treatment of at least 6 major disease
groups including CNS disorders, pain, airway disease, urinary incontinence, emesis and
intestinal disfunction [Patacchini & Maggi, 2001].
The percentage sequence identity between bovine rhodopsin and the NK1 receptor is
21 %, considering only the transmembrane regions, it rises to 27 %. In the case of
soluble proteins, pronounced structural similarity is generally given among proteins
with > 25% sequence identity, but below this level of sequence identity, structural
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divergence increases rapidly [Wilson et al., 2000; Yang & Honig, 2000a]. Nevertheless,
recent work has demonstrated that a number of different soluble proteins can achieve
the same fold with different sequence patterns [Yang & Honig, 2000b]. This holds also
for GPCRs [Oliveira et al., 2002]. In GPCRs, each helix contains one or more highly
conserved residues that allow for an unambiguous alignment of the helices of the model
and the bovine rhodopsin template. Therefore, it seems reasonable to assume that the
transmembrane region is very similar among all GPCRs.
4.1.3 NK1 antagonists
Meanwhile, a variety of NK1 antagonists have been developed based on several diverse
lead structures (for an overview, see [Giardina et al., 1997]). Although distinct in
their chemical scaffolds, they are similar in their interaction geometries. A generally
accepted pharmacophore model for non-peptidic NK1 antagonists is depicted in Fig.
4.4 [Boks et al., 1997]. It consists of at least two aromatic rings kept in fixed orientation
by various scaffolds, and contains at least one hydrogen-bond acceptor.
Table 4.2 gives some examples for antagonists binding with high affinity to the NK1
receptor. In Fig. 4.4, the key pharmacophoric elements are coloured according to the
given pharmacophore definition. Besides these pharmacophoric elements, a remarkable
structure-activity relationship for the ligands binding with high affinity is given with
respect to the substitution pattern at the phenyl rings. In compounds 4, 5, 6, 7, and 8
(Table 4.2), the phenyl ring is 3,5-bis(trifluoromethyl)-substituted. On the other hand,
compounds 2 and 3 are 2-methoxylated. The substitution pattern at the phenyl ring
seems to take a strong impact on binding affinity.
The influence of an appropriate phenyl substitution is demonstrated by examples given
Table 4.1: Tachykinins and their receptors
Receptor endogenous
ligand
sequence of the ligand
NK-1 substance P Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
NK-2 Neurokinin-A His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2
NK-3 Neurokinin-B Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2
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in Table 4.3. If the phenyl ring of the tryptophane-benzyl-esters is 3,5-bis-methyl-
substituted, affinity increases at least by 6-fold, replacing the methyl groups by trifluor-
methyle even results in a 40-fold affinity increase. In another series, compound 14 has
a 40-fold increased affinity compared to the unsubstituted phenyl ether 13. Here, no
remarkable change in affinity was observed when substituting the methyl by trifluor-
methyl groups (compound 15). Furthermore, the compounds in Table 4.3 show that
affinity can be increased by substituting the exocyclic nitrogen atom. Introduction of
a N-acetyl group to compound 10 enhances its affinity by more than 20-fold (11), the
same increase is observed when attaching the carboxamidomethyl to compound 15 (cf
16).
The first active NK1 antagonist was CP-96345, which was found in 1991 in a high-
throughput screening at Pfizer [Snider et al., 1991]. It is probably the best studied
NK1 antagonist. The binding of several derivatives of CP-96345 was measured to
obtain insight into the features responsible for binding (for example, see Table 4.4, 90)
[Swain et al., 1995; Lowe et al., 1992; Seward et al., 1993; Fong et al., 1993, 1994b; Lowe
et al., 1994]. Mutational studies and affinity measurements of derivatives of CP-96345
revealed the key roles of Gln165 [Fong et al., 1994a], His265 [Fong et al., 1994b], and
His197 [Fong et al., 1993] in binding of the quinuclidine antagonists. Several groups
have constructed a putative interaction model based on the skeleton of CP-96345 and
the amino acids essential for binding have been highlighted [Elliott et al., 1998; Takeuchi
et al., 1998; Swain et al., 1995; Jacoby et al., 1997; Vedani et al., 2000; Boks et al.,
1997]. An interaction model, constructed in our group, is depicted in Fig. 4.5. It is
based on the mutational data available in literature and is in agreement with the other
Figure 4.4: Generalised pharmacophore for non-peptidic NK1 antagonists. Two aro-
matic rings are connected via various scaffolds (left). A more detailed pharmacophore
contains at least one hydrogen-bond acceptor within the scaffold (right).
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published models.
Figure 4.5: Schematic representation of the postulated NK1-receptor-ligand inter-
actions for CP-96345. The arrows indicate proposed key interactions between the
receptor and the ligand.
In this interaction model, Gln165 establishes a hydrogen bond with the exocyclic sec-
ondary amine. As high affinity is also obtained when this secondary amine is replaced
by an oxygen, Gln165-NH probably acts as a donor and the amine-nitrogen as ac-
ceptor. The benzhydryl group of CP-96345 performs an amino-aromatic interaction
with His197 which is kept in place by an aromatic-aromatic interaction with Tyr272
[Fong et al., 1993]. The interactions of the aromatic moiety C with Ile204 [Holst et al.,
1998; Greenfeder et al., 1998] and His265 [Fong et al., 1994b] are obviously not spe-
cific. Instead, these residues seem to be part of a hydrophobic pocket. The aromatic
moiety A occurs in several NK1 antagonists, but is obviously not necessarily required
for high affinity. Supposedly, it serves as conformational anchor, but does not experi-
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ence any specific interactions with the receptor. Furthermore, an ionic interaction (or
a charged-assisted hydrogen-bond) between the positively charged quinuclidine nitro-
gen and a corresponding counterpart in the receptor is possible [Boks et al., 1997]. A
putative candidate is Glu193, however, mutational data do not definitely support this
assumption [Elling et al., 1995; Greenfeder et al., 1998]. Another explanation could
be that this part of the ligand interacts with residues from the extracellular loop or it
is exposed to the solvent. The latter hypothesis is supported by the observation that
a range of diverse polar substituents at the nitrogen is well tolerated [Giardina et al.,
1997].
A detailed study of the bioactive conformation of CP-96345 (and other antagonists)
was performed by Boks et al. [Boks et al., 1997]. They analysed small molecule crystal
structures of NK1 antagonists with respect to the intermolecular interactions of their
pharmacophoric groups with neighbouring molecules in the crystal packing. The most
striking feature is the relative orientation of the two aromatic rings to each other (B
and C in Fig. 4.5). Three distinct conformations are observed in crystal structures
for CP-96345 and two closely related derivatives, which exhibit distinct orientations of
the aromatic ring C. In one case, a conformation with parallel orientation is observed,
in the other two cases orientations with perpendicularly oriented rings are found (see
Fig. 4.6).
In another study, a conformational search was undertaken by Swain et al. to identify
the most favourable conformation of CP-96345 [Swain et al., 1995], however, no clear
preference for any of the two possible orientations has been found. Modelling studies
performed by Sisto et al. on a series of peptides and nonpeptides indicate that the
aromatic moieties exhibit a parallel stacking with respect to each other [Sisto et al.,
1995]. This assumption was further evidenced by ultraviolet absorption and fluores-
cence measurements. These findings suggest that the conformation adopted in the
crystals of LEWCUL (CSD refcode, see Fig. 4.6) matches best the given requirements
at the binding site of the NK1 receptor.
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Figure 4.6: Superimposed small molecule crystal structure conformations of CP-
96345. The CP-96345 free base (coloured yellow, CSD Refcode YAFJOE, [Lowe et al.,
1992]), the CP-96345 dimesylate salt (orange, YAFJUK [Lowe et al., 1992]), and the
N-methyl analogue of CP-96345 (cyan, LEWCUL, [Natsugari et al., 1995]) are shown.
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Table 4.2: Examples of NK1 antagonists from diverse structural classes.
No. compound IC50 [nM] No. compound IC50 [nM]
1 12 5 0.53
2 0.6 6 0.21
3 0.06 7 0.05
4 1.3 8 1.0
The compounds are extracted from the following references: 1: [Ofner et al., 1996],
2: [Williams et al., 1994], 3: [Desai et al., 1992, 1993], 4: [Natsugari et al., 1995], 5:
[Ward et al., 1995], 6: [Ladduwahetty et al., 1996], 7: [Swain et al., 1993], 8:
[Stevenson et al., 1995].
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Table 4.3: Effect of introducing appropriate substituents to increase affinity to
the NK1 receptor.
No. compound IC50 [nM] No. compound IC50 [nM]
9 > 10000 13 400
10 1533 14 9.3
11 67 15 10.7
12 1,6 16 0.53
The compounds are extracted from the following references: 9, 10, 11, 12:
[MacLeod et al., 1993], 13, 14, 15, 16: [Williams et al., 1994].
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4.2 Modelling the neurokinin-1 receptor
In chapter 3, we have presented MOBILE, an approach for homology modelling of
protein binding-sites including information about bioactive ligands. In the following,
we describe in detail the application of this approach to the NK1 receptor, which
belongs to the family of the G-protein coupled receptors.
The quality of the NK1 model and, thus, a critical evaluation of theMOBILE approach,
is accomplished by probing the ability to find novel antagonists with this homology
model. This task is realised by performing a virtual screening based on the modelled
receptor structure and a subsequent biochemical testing of a limited number of selected
hits.
Considering the fact that G-protein coupled receptors represent one of the most relevant
classes of pharmaceutic drug targets, the present study provides a particular challenge
for homology modelling with respect to structure-based drug design. This holds in
particular for the NK1 receptor, as its overall sequence identity to bovine rhodopsin
is only 21 % and in the region of the NK1 antagonist binding pocket no homology is
given. A successful application of the MOBILE procedure to the NK1 receptor would
therefore open a new perspective for the discovery of novel antagonists for any member
of the GPCR family.
4.2.1 Generation of protein-ligand complexes using the
MOBILE approach
Sequence alignment
The sequence alignment (see Fig. 4.7), generated automatically with PSI-BLAST
[Altschul et al., 1997] and IMPALA,[Schaffer et al., 1999] was taken from a previously
produced homology model of the NK1 receptor deposited in ModBase [Pieper et al.,
2002] (database accession number P25103). The alignment was slightly modified in
the region of the β4-hairpin following the recommendations of Oliveira et al. [Oliveira
et al., 2002] (see section 4.1.1).
As apparent from the mutual alignment, the sequences are most divergent in the ex-
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tracellular regions. No gaps or insertions are predicted in the TM regions. However,
in the antagonist binding-site region (residues marked grey in Fig. 4.7), no matching
residues are conserved.
Figure 4.7: Sequence alignment of bovine rhodopsin and the NK1 receptor. All
residues comprising the putative binding pocket of CP-96345 are marked gray. The
amino acids known from mutational studies to be essential for CP-96345 binding are
labelled with an asterisk.
Generation of preliminary NK1 models
A set of 100 initial protein models of the NK1 receptor were generated using MOD-
ELLER [Marti-Renom et al., 2000; Sali & Blundell, 1993; Fiser et al., 2000]. According
to the algorithms implemented into MODELLER, structures of slightly deviating ge-
ometry are subjected to the optimisation step. In total, 100 different structures are
finally obtained, which reflect - to some extend - the conformational variability in of
those regions which differ in the sequence alignment. For those regions which align
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in the sequence space, but with different amino acids (i.e. no insertion or gap), the
backbone coordinates will remain close to those of the template coordinates, whereas
the conformational space of the side-chain atoms is exhaustively sampled. Thus, an
ensemble of 100 binding-site models of the NK1 receptor was produced (see Fig. 4.8).
Visual inspection of the generated models in particular of the residues known by mu-
tational studies to be involved in antagonist binding [Garret et al., 1991; Snider et al.,
1991; Cascieri et al., 1992; Fong et al., 1992; Gether et al., 1993a; Fong et al., 1993;
Zoffmann et al., 1993; Gether et al., 1994b,a; Huang et al., 1994; Fong et al., 1994a,b;
Gether et al., 1993b; Holst et al., 1998; Greenfeder et al., 1999] confirmed the rele-
vance of our sequence alignment: The spatial arrangement of the modelled binding-site
residues is in good agreement with the pattern of the proposed interaction models used
to describe CP-96345 binding (Fig. 4.5). Fig. 4.8 (left) shows the backbone of one NK1
model together with an ensemble of orientations of those residues which are known to
be involved in antagonist binding. The backbone trace of the putative β4-hairpin is
coloured red.
Since the NK1 receptor model was generated by homology, the geometry generated for
the β4-hairpin has been directly transferred from the bovine rhodopsin template struc-
ture. Its geometry appears unlikely for the modelled receptor since it would prevent
antagonist binding in the present close-up conformation. This detail of the modelled
receptor points to the limitations in protein structure prediction by homology., however
it is not crucial for the present modelling attempt since mutational studies do not give
hints for specific interactions with CP-96345.
Placing the ligand into the preliminary homology models
The next step following our MOBILE approach, outlined in chapter 3, would be to
dock a ligand flexibly into an averaged ensemble of preliminary NK1 models. However,
this procedure is not reasonable in the case of the NK1 receptor. As the conformational
space of the residues defining the NK1 antagonist binding-site is exhaustively sampled,
the averaged ensemble is too diffuse to allow for precise docking. Therefore, the ligand
was docked into each single NK1 model using AutoDock 3.0 [Morris et al., 1996] with
DrugScore pair potentials serving as objective function. The E2 loop (containing the
β4-hairpin) as described is not essential for the present modelling study, thus it was
removed from the models for the following docking procedure.
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Figure 4.8: Homology models of the NK1 receptor. left: The backbone (cyan) and an
ensemble of 100 side-chain residue conformers involved in binding CP-96345 is shown;
right: Four docking solutions of CP-96345. Their orientations agree well to the muta-
tional data and the proposed interaction model shown in Fig. 4.5. The ensemble of the
binding-site residues crucial for binding CP-96345 is depicted: Gln165, Glu193, His197,
Ile204, His265, and Tyr272.
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To reduce the search space, CP-96345 was kept rigid for the docking into the initial
homology models, simultaneously assuming that its bound conformation is similar to
that observed in the crystal structure (LEWCUL) [Natsugari et al., 1995], i.e. the
aromatic rings are supposed to be oriented in parallel to each other (see Fig. 4.6).
Finally, the docking solutions were inspected visually, evaluating the obtained agree-
ment with the interaction model based on the published mutational data [Elliott et al.,
1998; Takeuchi et al., 1998; Swain et al., 1995; Jacoby et al., 1997; Vedani et al., 2000;
Boks et al., 1997] (4.5). A total of four solutions with alternative orientations of the
side-chains of the protein binding-site residues (see Fig. 4.8 (right)) were selected for
the subsequent protein modelling step.
Generation of refined NK1 models including ligand information and
optimisation of the modelled protein-ligand complexes
In the next step, for each of the four selected docking poses, 100 new homology models
were generated. According to the MOBILE approach, ligand information was con-
sidered as additional restraint in the homology modelling procedure. The 400 thus
generated protein-ligand complexes were further refined. First, to each amino acid a
DrugScore value was assigned to describe the interaction with the ligand. It was then
used to restrain the protein modelling step. Subsequently the best individual solutions
from the different models were combinatorially assembled, and finally the composed
complex was selected which yielded the best total DrugScore value avoiding any in-
tramolecular clashes between the individual amino acid side-chains from the different
models. In order to relax the composed model, the entire binding pocket was min-
imised with the MAB force-field available in Moloc [Gerber, 1998; Gerber & Mu¨ller,
1995], keeping the ligand and the protein residues flexible.
4.2.2 Analysis of the model
Analysis of the global fold of the model
As we applied the principle of homology modelling, the length and geometry of the
transmembrane region is produced very similarly to that in bovine rhodopsin. As
outlined in section 4.1.1, considering the conservation of key residues in the family of
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GPCRs, there are good reasons to assume that the geometry of the transmembrane
region will be conserved among these receptors. This assumption is supported by the
fact that all GPCRs couple to the same protein (the G-protein). Furthermore, it is
likely that all GPCRs follow a similar G-protein activation mechanism [Oliveira et al.,
2002]. In consequence, it can be assumed that the inactive state of the NK1 receptor
(as for all GPCRs) corresponds to the inactive state of bovine rhodopsin captured in
the crystal structure and which was used as template in our modelling process. As
we are interested in finding antagonists, which should stabilise the NK1 receptor in
its inactive state, the crystal structure of bovine rhodopsin as reference appears well
suited.
The confidence in the geometry of the extracellular loops (including the β4-hairpin)
is very low, in contrast to the transmembrane region. This holds in particular for
the extra-cellular regions. Considering that all endogenous agonists interact with the
extracellular region of their receptor and recalling that these agonists are rather diverse
with respect to different GPCRs, it is very likely that GPCRs are very different in this
region. From this point of view, it seems very unlikely that the extracellular loop
regions adopt similar orientations in all GPCRs. Furthermore, it must be considered
that the conformation adopted by the extracellular loops in the crystal structure of
bovine rhodopsin is supposedly largely determined by crystal packing forces. However,
it has been noticed that for the attempted modelling of the antagonist binding site
the assumed loop conformations are of no direct relevance since no specific interactions
with NK1 antagonists are suggested in literature.
Analysis and validation of the active site and modelled protein-ligand
complex
The complex of the NK1 model, including the six residues known to be crucial for
binding CP-96345, is depicted in Fig. 4.9. The proposed interactions (as suggested by
the interaction model, Fig. 4.5) are displayed as dashed lines. As mentioned above, no
sequence identity between NK1 receptor and bovine rhodopsin is given in the antagonist
binding pocket. Thus, the backbone trace of the NK1 model is closely related to
the rhodopsin template, but no restrictions for the orientation of the active-site side-
chains is provided by the homology model. Since the NK1 model was generated and
optimised to produce a binding pocket that exhibits optimal interactions with CP-
96345, the arrangement of these side-chains is predominantly determined by the docked
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binding mode of this ligand. The finally achieved spatial arrangement of the binding-
site residues agrees well with the topographic interaction model depicted in Fig. 4.5:
All residues known to be crucial for CP-96345 binding are in direct contact with the
ligand in our model. This fact retrospectively confirms the relevance of the assumed
sequence alignment.
As indicated by the mutational studies, the most important interaction between NK1
receptor and antagonists is the hydrogen-bond between the Gln165-NH and a hydrogen-
bond acceptor of the antagonist. This interaction is well reproduced by our model as
indicated in Fig. 4.10. The distance between the Gln165-NH and the nitrogen N2
(dashed lines, see Fig. 4.9) amounts to 3.21 A˚. Also, our model reproduces the sug-
gested amino-aromatic interactions [Fong et al., 1993], which are established between
the aromatic rings A and B and His197, which is in turn stabilised by an aromatic-
aromatic interaction with Tyr272. The role of His267 and Ile204 and their interactions
with the ligand are not clear. In agreement with mutational data, instead of specific in-
teractions, hydrophobic interactions between the aromatic moiety C and His264/Ile204
are established. A possible ionic interaction between the nitrogen N1 and a correspond-
Figure 4.9: Modelled complex of the NK1 receptor with CP-96345 The dashed lines
indicate the key interactions of the proposed interaction model depicted in Fig. 4.5.
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ing protein partner is not fully evidenced, neither by the mutational data nor by our
model (the distance to the Glu193-carboxy oxygen amounts to 5.58 A˚). The mutational
data show that a slight change in affinity is detected when Glu193 is mutated to Ala
or His [Elling et al., 1995; Greenfeder et al., 1998], however, as this decrease is not
significant (less than 3-fold and 7-fold), and the ionic interaction cannot be reproduced
by our model, N1 is possibly exposed to the solvent and does not directly interact with
Glu193 or another amino acid.
As indicated above, it is unlikely that the orientation of the the β4-hairpin is similar in
bovine rhodopsin and the NK1 receptor. Indeed, in our modelled complex, CP-96345
would clash with the β4-hairpin if it would adopt the same orientation as the crystal
structure of bovine rhodopsin (see Fig. 4.8). It was shown by Cavasotto et al. that reti-
nal can be docked accurately into the bovine rhodopsin pocket even if the N-terminus,
C-terminus, and extracellular (including the β4-hairpin) and intracellular loops are re-
moved [Cavasotto et al., 2003]. Even though retinal is in contact with the β4-hairpin in
the rhodopsin crystal structure, the majority of the ligand is deeply buried and bind-
ing is sufficiently determined by contacts established to the transmembrane part of the
receptor. This fact suggests that these features can be used to identify ligands on the
basis of a sufficiently accurate homology model of the NK1 receptor. This assumption
is further supported by the observation that mutations within the β4-hairpin of the
NK1 receptor did not result in any specific interactions with CP-96345. Consequently,
one option for structure-based drug design would be to fully neglect this region in the
search for new antagonists. This, however, could provoke docking solutions for ligands
that are artificially oriented into unoccupied region. Therefore, to restrict the binding
pocket to some degree, however simultaneously to avoid specific interactions with the
binding site of CP-96345, we manually placed the β4-hairpin loop in a somewhat dis-
tant region. Subsequently, the corresponding residues were relaxed using the AMBER
force-field [Weiner et al., 1986] to avoid unreasonable interaction geometry. In the fol-
lowing virtual screening procedure, the relevance of the docked ligands was evidenced
not by solely evaluating the interactions between protein- and ligand-atoms but in
particular by considering their similarity with known NK1 antagonists (see section ).
To further assess the relevance of the produced model, we examined its ability to
accommodate other known NK1 antagonists. Two different sets of antagonists were
docked into the active site. The first data set comprised known NK1 antagonists listed
in Table 4.2. A second set has been composed by quinuclidine derivatives of CP-96345
(see Tab. 4.4). The ligands were placed using FlexX-Pharm [Hindle et al., 2002],
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restraining the docking procedure by defining an essential hydrogen-bond interaction
between the Gln165-NH and a hydrogen-bond acceptor in the ligand. As base fragment
for the incremental construction algorithm of FlexX, the aromatic ring B was used in
the docked orientation of CP-96345 (Fig. 4.9) using the mapref mode in FlexX. In
all cases, reasonable orientations were obtained. In addition, based on the docking
solutions, the trends in binding affinity could be reproduced qualitatively.
4.2.3 Generation of a protein- and ligand-based
pharmacophore
Based on the modelled NK1–CP-96345 complex, a structure-based pharmacophore
model has been generated considering the mutational data from literature and the
common features of known NK1 antagonists, which are assumed as prerequisite for
binding.
This pharmacophore model is characterised by the following three features (see Fig.
4.5 and 4.10):
• A hydrogen-bond between the Gln165-NH and a corresponding acceptor of the
ligand (N2 in CP-96345). The hydrogen-bond between Gln165-NH and the NK1
antagonists are indicated to be essential by Fong et al. [Fong et al., 1994a].
This assumption is best demonstrated by the observation that replacing N2 in
CP-96345 by a carbon atom (compound 24 in Table 4.4) results in a dramatic
decrease in affinity (0.52 to > 32000 nM).
• The aromatic moiety B which interacts with His197 via amino-aromatic interac-
tions [Fong et al., 1993].
• A second aromatic group (C) which falls next to His265 [Fong et al., 1994b] and
Ile204 [Holst et al., 1998; Greenfeder et al., 1998]. Obviously it does not form
specific interactions to His265, but favourable interactions are observed for CP-
96345 analogs that show substituents at ring C. Although the kind of interaction
is not clear, analysis of known NK1 antagonists reveals that an aromatic moiety
C is essential for high-affinity binding to the NK1 receptor.
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Figure 4.10: Structure-based Pharmacophore hypothesis The H-bond interaction be-
tween GLN165-NH (cyan sphere) and a corresponding H-bond acceptor (red) is consid-
ered essential for all NK1 antagonists. The aromatic moieties are indicated by yellow
spheres.
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4.2.4 Virtual Screening
In the present study, about 800000 candidate molecules, assembled from seven dif-
ferent databases, were screened to search for NK1 antagonists. The same compounds
were previously screened in our group to search tRNA-guanine transglycosylase (TGT)
inhibitors [Brenk et al., 2003].
Similar to the studies of Brenk et al. [Brenk et al., 2003] and Gru¨neberg et al.
[Gru¨neberg et al., 2002], the screening has been performed in a stepwise fashion using
Selector [Selector, 1996], Unity [UNITY, 2001], and FlexX-Pharm [Hindle et al., 2002]
and included several hierarchical filters of increasing complexity with respect to their
computational requirements.
The initial step, a rather unspecific and target-independent filter, was already applied
by Brenk et al. [Brenk et al., 2003]: Only compounds with up to seven rotatable bonds
and a molecular weight of less than 450 Da have been considered. The reason for these
criteria is to retrieve hits small enough to allow for further optimisation, thus focusing
on ”leadlike” hits [Oprea et al., 2001; Hann et al., 2001]. Furthermore, highly flexible
ligands are avoided as they possibly (1) reveal reduced binding affinity due to entropic
considerations and (2) increase the complexity of the attempted 3D search procedures.
A further rationale to restrict flexibility arises from the experience that the reliability
of accurate docking diminishes with increasing degrees of freedom to be considered in
the search procedure. Almost 50 % of the initial compounds were eliminated by this
filter.
In a second step, a topological filter was applied according to the pharmacophore
requirements given in Fig. 4.5. Only candidate molecules comprising at least (a)
two phenyl rings and (b) one hydrogen-bond acceptor were further considered. This
reduced the list of prospective compounds to about 16 % of the initial set.
The 3D protein- and ligand-based pharmacophore model (Fig. 4.10) was used in the
following step to constrain the mutual spatial arrangement of the aromatic rings and
the hydrogen-bond acceptor. In a fourth step, receptor information was explicitly
included by restraining the directionality of the hydrogen-bond (to interact with the
Gln165-NH) and by considering excluded volume constraints. The number of hits in
agreement with this filter contained 11109 compounds. Accordingly, the hierarchical
filtering procedure reduced the databases to 1.34 % of their original size (Table 4.5).
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Table 4.4: Quinuclidines and analogues that were used for model validation.
No. compound IC50 [nM] No. compound IC50 [nM]
17 0.8 22 > 1000
18 246 23 85
19 20 24 > 32000a
20 1.6 25 12.2b
21 106 26 332b
Affinities of compounds 17 – 23 were derived from inhibition of [125I]SP binding
(IC50 of CP-96345: 0.8 nM); [Swain et al., 1995]. a) compound 24 was measured
against [3H]SP (IC50 of CP-96345: 0.77 nM) [Lowe et al., 1992] and b) affinities of
compounds 25 and 26 were measured against [125I]BHSP (IC50 of CP-96345: 0.52
nM) [Lowe et al., 1994].
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Table 4.5: Statistical Overview of the Results from Sequential Application of a Series of Hierarchical Filters on the Seven
Considered Databases
ACD AMBINTER AEGC AEPC
filter step no. of compds [%] no. of compds [%] no. of compds [%] no. of compds [%]
215212 100.00 115815 100.00 182485 100.00 44549 100.00
1. rotatable bonds/ MW 135502 62.96 59877 51.70 91677 50.24 9417 21.14
2. requested no. of hydrophobic,
donor and acceptor properties 30878 14.34 19764 17.07 36302 19.89 2740 6.15
3. pharmacophore hypothesis 8645 4.02 5353 4.62 10534 5.77 1018 2.29
4. excluded volumes 3084 1.43 1510 1.30 2998 1.64 334 0.75
continuation Table 4.5
ChemStar IBS LeadQuest [
∑
]
filter step no. of compds [%] no. of compds [%] no. of compds [%] no. of compds [%]
57927 100.00 158942 100.00 52002 100.00 826952 100.00
1. rotatable bonds/ MW 28712 49.57 76321 48.02 18231 35.04 419747 50.76
2. requested no. of hydrophobic,
donor and acceptor properties 11229 19.38 24571 15.46 6483 12.47 131967 15.95
3. pharmacophore hypothesis 3547 6.12 5463 3.44 2144 4.12 36704 4.44
4. excluded volumes 1226 2.12 1362 0.86 595 1.14 11109 1.34
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The remaining compounds were docked into the binding-site of our NK1 homology
model. To obtain only hits which agree with our 3D pharmacophore model, we used
FlexX-Pharm for docking, which allows the incorporation of constraints derived from
pharmacophore features. Based on our 3D protein- and ligand-based pharmacophore
model (Fig. 4.10), the following features were included: The phenyl ring B was defined
as base fragment for the incremental construction algorithm of the docking procedure.
This was accomplished using the phenyl ring coordinates of the initially modelled ori-
entation of CP-96345 applying the mapref command in FlexX. The hydrogen-bond
between Gln165-NH and a composite hydrogen-bond acceptor was constrained as es-
sential hydrogen-bond interaction. The orientation of the aromatic ring (C) was not
constrained in order to reduce the bias on the system and to assess whether reasonable
orientations for this moiety can be generated by FlexX-Pharm using other molecular
skeletons and considering the protein environment as constraints.
All docking solutions were scored with DrugScore [Gohlke et al., 2000a]. DrugScore
scales within the size of the ligands in contact with the protein. We therefore normalised
the score with respect to the number of non-hydrogen atoms in each placed candidate
ligand [Pan et al., 2002].
For the 1000 best-ranked ligands, the best docking solutions were minimised with the
MAB force-field available in Moloc [Gerber, 1998; Gerber & Mu¨ller, 1995] keeping the
ligand and the binding-pocket (i.e., all residues within 6 A˚ around the ligand) flexible.
The purpose of this procedure was (1) to optimise the local interactions and (2) to
account for protein flexibility induced by ligand binding.
The minimised solutions were very quickly checked visually rejecting those poses which,
did not show the aromatic ring C in parallel orientation to ring B as depicted in Fig.
4.10.
The remaining ∼ 250 solutions were inspected more carefully considering the follow-
ing aspects. Ideally, the selection of virtual screening hits could be solely based on
the ranking of the scoring function used to evaluate the interaction geometry of the
docked ligands. However, many binding features in the protein-ligand interface are
yet not fully understood and certain observations cannot be reproduced adequately
enough by current scoring functions. Furthermore, it has been shown that the perfor-
mance of a scoring function possibly depends on binding characteristics present in a
particular protein-ligand interface, such as hydrophobicity, hydrophilicity, dominance
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of electrostatic/H-bond properties, etc. [Stahl & Rarey, 2001; Schulz-Gasch & Stahl,
2003]. In addition, general observations from quantitative structure-activity relation-
ships prompted us to carefully inspect the best hits from the virtual screening with
special regard to the following characteristics:
• An amino-aromatic interaction should be given between His197 and the aromatic
moiety B. This type of interaction is not yet parameterised and validated in the
current scoring functions.
• Most scoring functions do not consider intramolecular interactions when eval-
uating protein-ligand interactions, in particular aromatic-aromatic interactions.
The described pi − pi-stacking, as observed between the aromatic moieties B and
C, seems to have a favourable impact on binding, thus its occurrence has been
requested.
• As the binding pocket and most interactions between the NK1 receptor and its
antagonists are mainly hydrophobic, the hydrogen-bond between Gln165-NH and
a corresponding acceptor was carefully analysed. This interaction seems to be
of utmost importance: as mentioned, upon replacement of N2 in CP-96345 by a
carbon atom (compound 24 in Table 4.4) affinity is dramatically reduced (0.52
to > 32000 nM). This is probably beyond the scope of any scoring function.
• As the model is not reliable next to the region of the β4-hairpin, parts of the
ligands placed into this region were evaluated with respect to a given similarity
with known NK1 antagonists.
We furthermore focused on ligands with a limited number of rotatable bonds to avoid
entropically disfavourable binding due to pronounced conformational immobilisation.
Applying these criteria in a thorough visual inspection of the retrieved candidates, the
seven compounds listed in Table 4.6 were selected for biochemical testing.
4.2.5 Testing for binding
As assay a radioligand binding assay on whole CHO (Chinese Hamster Ovary) cells
(with substance P as radioligand) has been performed. This assay is only sensitive to
detect ligands of at least 1 µM potency. Any binding beyond this rather stringent limit
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cannot be detected. Out of the seven selected compounds, one (29) shows 0.25 µM
affinity.
Compound 29 agrees well with the 3-dimensional pharmacophore model. Comparing
compound 29 and CP-96345 in their docked orientations reveals that the aromatic moi-
eties and the position of the hydrogen-bond acceptor superimpose well. Even the pos-
tulated amino-aromatic interaction between His197 and the aromatic ring is matched
similarly to CP-96345. The hydrogen-bond with Gln165-NH is established via the
peptide carbonyl oxygen (see Fig. 4.11). Besides, the sulfur of the thioether-group
could be involved as further hydrogen-bond acceptor. The peptide bond rigidifies the
ligand’s skeleton and possibly has a favourable impact on the entropic contribution to
binding. Considering the docked geometry of 29, both aromatic moieties (B and C
in the pharmacophore model) exhibit a parallel arrangement, however they are shifted
with respect to each other in a way that they do not establish a pi − pi-stacking inter-
action. Instead, according to our model, the aromatic ring B stacks upon the pi-face of
the peptide bond. In addition, 29 exhibits an aromatic moiety A (Fig. 4.10) that is
present in several NK1 antagonists. It is obviously not mandatory for high affinity. As
mentioned before, it probably serves as conformational anchor, but does not perform
any specific interaction with the receptor. Interestingly enough, besides 27, it is the
only one out of the seven tested compounds that possesses this moiety.
Figure 4.11: Modelled binding mode of ASN-1377642, which was identified as novel
submicromolar NK1 antagonist by virtual screening. The orientation with respect to
the modelled binding pocket is shown (left). On the right, the modelled superimposition
of ASN-1377642 and the known NK1 antagonist CP-96345 is shown.
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4.2.6 Discussion
In this contribution, we present a strategy for the computer screening of large com-
pound libraries for the NK1 receptor. This receptor belongs to the family of G-protein
coupled receptors, which represents one of the most important pharmaceutical drug
target classes. Our approach, which can in principle be applied to any member of the
GPCR family to produce a geometry of the receptor in an inactive state, is based on a
homology model generated on the basis of the crystal structure of bovine rhodopsin as
structural template. The NK1 model was constructed under explicit consideration of
ligand information applying our recently developed MOBILE (Modelling Binding Sites
Including Ligand Information Explicitly) approach described in chapter 3 of this thesis.
The model was validated by reproducing experimental information such as mutational
data and corresponding affinity data of known ligands. It was successfully used to
screen seven databases containing in total about 800000 compounds. Docking yielded
one novel compound (out of seven selected, biochemically tested hits) that binds to
the receptor in the submicromolar range. Any binding of the other tested hits in an
affinity range beyond 1 µM could be possible, however it is out of the detection limit
of the applied assay conditions.
Similar computer-aided screening approaches have previously been performed in our
group to discover novel inhibitors for the tRNA-guanine transglycosylase (TGT) [Brenk
et al., 2003] and carbonic anhydrase II [Gru¨neberg et al., 2002]. Both studies were based
on available high-resolution crystal structures of protein-ligand complexes. The search
strategy applied in the present contribution is somewhat different in certain steps of
the screening to account for potential structural uncertainties of the homology model.
We started with the generation of preliminary protein models and subsequent docking
into these crude models and finally generated a refined protein-ligand complex consis-
tent with experimental data. This modelled complex served as a platform to generate
a hybrid protein- and ligand-structure-based pharmacophore model and as structural
grounds for the following database search. Thus, in our approach, ligand information
was not only explicitly included in the protein modelling step but also considered in
the screening and scoring procedure. In the initial screening only those compounds
out of 800000 database entries were selected, that agreed to simple 2D pharmacophore
features established as minimal requirement due to the analysis of known NK1 antag-
onists. In subsequent steps, ligand information was taken into account by applying
3D pharmacophore features derived from the analysis of the putative binding mode of
96 4.2 Modelling the neurokinin-1 receptor
the ligand CP-96345, complexed with our NK1 model. In contrast to the approach
followed by Brenk et al. and Gru¨neberg et al., these pharmacophore features were also
used to constrain the docking procedure within FlexX-Pharm. As a further difference
to the above-mentioned studies, the entire protein-ligand complexes were minimised
using the MAB force-field to consider possible adaptations of the protein induced by
ligand binding and to subsequently account for potential structural deficiencies of the
model. Finally, the docked solutions were carefully inspected considering the agree-
ment of their pharmacophoric features with the putative interaction features present
in known active NK1 antagonists. Considering the fact that CP-96345 and compound
29 are similar with respect to their pharmacophoric features, but different with respect
to their molecular skeletons, we believe that our hit would not be retrieved as one of
the top hits using a solely ligand-based or a solely protein-based screening approach.
Primary focus of this study was to demonstrate that ligand-supported homology mod-
elling of the target receptor can be accomplished successfully for GPCRs using our
MOBILE approach. The discovered lead structure 29 has yet not been further opti-
mised. This could involve, as outlined in section 4.1.3, a remarkable affinity increase
by introduction of a 3,5-bis(trifluoromethyl)-substitution at the aromatic moiety C.
Swain et al. suggested as possible explanation of this observation that a particular
arrangement of the aromatic moieties B and C with respect to each other is favoured
or that lipophilic contacts with His265 can be established [Swain et al., 1995]. Further
optimisation of binding of 29 could be attempted by appropriate substitution of one of
the nitrogen atoms at the triazole ring by attaching a N-acetyl or carboxamidomethyl
group (cf examples in Table 4.3).
The applied procedure of combining information from bioactive ligands and the knowl-
edge about the 3D structure of bovine rhodopsin, along with mutational data, provides
a new perspective to drug discovery of GPCR ligands. Remarkably enough, the global
sequence identity between bovine rhodopsin and the NK1 receptor is 21 %. Consider-
ing the transmembrane region only, the identity increases to 27 %, however, regarding
only the modelled binding site of CP-96345, no sequence identity is given. Usually, if
sequence identity falls below 35 %, the accuracy of a homology model is considered not
sufficient enough to allow for virtual screening and docking of small ligands [Baker &
Sali, 2001]. In light of this non-conserved antagonist binding area among NK1 recep-
tor and rhodopsin it is even more remarkable that our MOBILE approach produced a
binding-site geometry reliable and relevant enough to discover a submicromolar antag-
onist via structure-based screening methods.
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However, it must be noted that precise affinity prediction is not possible with our
model. To a certain extent, this is due to shortcomings of the currently available
scoring functions. Further limitations probably arise from the fact that towards the
β-hairpin, our model is very crude and approximative and not correctly reflecting the
native configuration of the protein.
An important binding determinant is the H-bond formed to Gln165. The mutational
and ligand data provide clear evidence that Gln165 acts as a donor [Bieler, 1998]. It
could furthermore serve as H-bond acceptor, depending on the side-chain orientation
of the terminal amide group and the composite group in the ligand. This has con-
sequences on the definition of the pharmacophore model used to specify the search
queries. In our search we requested an acceptor site in putative ligands. An alterna-
tive pharmacophore model could define an acceptor or donor site at this position and
serve as additional basis for the search of NK1 antagonists. Besides, in the 3D phar-
macophore model, the arrangement of the aromatic ring systems was assumed to be
parallel as observed in the small molecule crystal structure LEWCUL and confirmed by
experimental studies based on ultraviolet absorption and fluorescence measurements
[Sisto et al., 1995]. Nevertheless, the other two small molecule crystal structures in-
dicate that a perpendicular arrangement of these aromatic moieties to each other also
corresponds to a low-energy conformer. Accordingly it cannot be ruled out that the
latter geometry is also of relevance for the arrangement at the binding pocket. Neither
the available mutational data nor the local contacts to adjacent protein residues next
to both aromatic rings favours one of these arrangements.
Furthermore, it has to be mentioned that originally 15 compounds were selected for
biochemical testing. Due to inaccessibility or delivery problems of the commercial
suppliers, we could only obtain half of the requested compounds (7). The affinity de-
termination was performed using an assay with a detection limit beyond 1 µM affinity.
Since testing at higher concentrations was impossible to perform we cannot decide
whether the remaining six hits from our selection antagonise the NK1 receptor with
micro- or millimolar affinity. For the present feasibility study such information would
be desirable but even the test results on seven compounds would not allow for statistics
on the success rates of the present method. To demonstrate that homology modelling
using our MOBILE approach is capable to produce models of relevance for structure-
based virtual screening, the discovered hit which is in full agreement with the search
hypothesis is a remarkable and convincing result.
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Table 4.6: List of compounds that were tested for inhibition.
No. compound label (Database) DS
a)
(rank)
DS2 a)
(rank)
KB [nM]
27 ASN-2069941 (AEPC) -54.2 (10) -17.7 (9) > 1000
28 ASN-2069935 (AEPC) -52.7 (19) -17.3 (16) > 1000
29 ASN-1377642 (AEPC) -53.4 (15) -17.4 (15) 251
30 STOCK2S-25832 (IBS) -48.1 (42) -16.7 (29) > 1000
31 STOCK2S-20468 (IBS) -49.3 (35) -16.2 (37) > 1000
32 STOCK2S-74056 (IBS) -55.0 (6) -17.9 (7) > 1000
33 STOCK1S-23930 (IBS) -51.2 (24) -16.7 (30) > 1000
a) The original DrugScore values are divided by 10000.
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4.3 Modelling the neurokinin-2 receptor
Both, NK1 and NK2 receptors, appear to be involved in pulmonary pathophysiology.
Accordingly, agents that simultaneously antagonise NK1 and NK2 may have therapeu-
tic applications.
To understand the molecular basis of factors relevant to neurokinin selectivity, we
generated ligand-supported homology models of the NK2 receptor including knowledge
about mutational studies and the binding of the NK2-selective antagonist SR-48968
[Emonds-Alt et al., 1992]. Different sets of models were constructed, based (1) on the
structure of the previously generated homology model of the NK1 receptor (section
4.2) and (2) on the crystal structure of bovine rhodopsin [Palczewski et al., 2000;
Teller et al., 2001; Okada et al., 2002].
To obtain insights into the features determining selectivity between NK1 and NK2,
mutational and affinity data with respect to the following three ligands (Table 4.7) are
analysed: (1) the NK2-selective compound SR-48968 [Emonds-Alt et al., 1992], (2) the
dual NK1/NK2 antagonist ZD-6021 [Bernstein et al., 2001], and (3) the NK1-selective
CP-96345 [Snider et al., 1991].
4.3.1 Generation of protein-ligand complexes using the
MOBILE approach
Sequence alignment
Different sets of homology models were based on the sequence alignment depicted in
Fig. 4.12. This alignment was generated by CLUSTALW [Thompson et al., 1994]
keeping the relative positions of the NK1 receptor and bovine rhodopsin as in the
alignment depicted in Fig. 4.12 and realigning only the sequence of the NK2 receptor.
According to this alignment, the global sequence identity amounts to 56 %. According
to the overall strategy of our approach, initial sets of NK2 models were generated
without including ligand information into the homology modelling process.
Considering the corresponding 15 residues defining the antagonist binding pocket in
the NK1 receptor, the sequence identity between the binding sites of the NK1 and NK2
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Table 4.7: Ligands binding to the neurokinin receptors
ligand structure KB [nM] (NK1) KB [nM] (NK2)
ZD-6021 1.0 5.5
SR-48968 > 10000 0.7
CP-96345 8.1 > 10000
Affinity measurement of ZD-6021 ([Bernstein et al., 2001]) was performed with a
different assay than measurement of SR-48968 and CP-96345 ([Gether et al.,
1993b]). The absolute affinity values can thus not be compared directly with each
other.
receptor is 75 %. As in the case of the NK1 receptor, the thus defined binding pockets
of the NK2 receptor and bovine rhodopsin lack any similarity.
Generation of preliminary NK2 models
Using MODELLER, 100 homology models of the NK2 receptor were constructed. For
the generation of these preliminary models, the homology model of the NK1 receptor
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Figure 4.12: Sequence alignment of bovine rhodopsin, the NK1, and NK2 receptor.
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(see section 4.2) served as a template. The rationale for such doing is the fact that
the sequence identity of the antagonist binding pockets between NK1 and NK2 is
rather high (75 %), whereas no identity is given among the binding pockets of the NK2
receptor and rhodopsin. This reduces the search space for the modelling procedure.
Not surprisingly, a binding cavity is defined by those amino acids, which are known
from mutational studies to be involved in SR-48968 binding (Gln166, His198, Tyr266,
His267, Phe270, Tyr289, and Phe293) (see Fig. 4.13).
Figure 4.13: Homology model of the NK2 receptor. left: the backbone (cyan) and
the ensemble of 100 conformers of 7 residues relevant for binding the NK2-selective
antagonist SR-48968 is shown: Gln166, His198, Tyr266, His267, Phe270, Tyr289, and
Phe293; right: binding pocket with two docking solutions of the core fragment of SR-
48968.
Placing the ligand into the preliminary homology models
A core fragment of SR-48968 (see Table 4.7) was flexibly placed into each individual
homology model. For this experiment, SR-48968 was docked with an unsubstituted
piperidine moiety, because experimental observations indicate that these substituents
interact with regions of the extracellular loops for which, due to the low sequence iden-
tity with rhodopsin, no reliable conformation can be obtained by homology modelling.
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Accordingly, the corresponding extracellular sequence stretch in the NK2 receptor was
not considered for the docking experiment.
The docking solutions were visually analysed. The major criterion to assess the rel-
evance of the modelled complex was the question whether the generated interactions
are in agreement with mutational data and preliminary assumptions about a pharma-
cophore model: Analysing selective NK1, NK2 as well as dual NK1/NK2 antagonists
(e.g. [Giardina et al., 1997]), the aromatic ring B in our pharmacophore model for the
NK1 receptor (see Fig. 4.10, p. 88) seems to be an essential pharmacophore element
with respect to both receptors, probably establishing an amino-aromatic interaction
with His197 (NK1), His198 (NK2), respectively. Also an H-bond seems to be essential
between SR-48968 and Tyr287. As most NK2 antagonist possess H-bond acceptors
at corresponding positions, this feature also appears mandatory for binding. On the
other hand, mutational data suggest that an H-bond with Gln166 (Gln165 in NK1)
is not essential. Two similar ligand geometries could be identified, which fulfilled the
required criteria (see Fig. 4.13).
Generation of refined NK2 models including ligand information and
optimisation of the modelled protein-ligand complexes
Assuming that the selected docking solutions resemble the native orientation in the
NK2 binding pocket, new ensembles of NK2 models were generated. In order to allow
for more conformational sampling of the binding site residues, this modelling step was
performed with bovine rhodopsin as structural template. Due to the fact that no
sequence identity between NK1 and bovine rhodopsin is given in the active site, the
conformational space of the referring residues was exhaustively covered.
The binding sites of the NK1 models were then further refined by optimising the
interactions with the two ligand orientations of SR-48968 retrieved from the initial
docking experiments. First, each amino acid was assigned a score (the DrugScore value
for the interaction with the actual ligand). Then, the best individual solutions from
the different models were combinatorially merged, and finally the model was selected
which yielded the best DrugScore value and did not show any intramolecular clashes
between the individual amino acid side-chains. In order to relax the system, the entire
binding pocket was minimised with the MMFF94 force-field [Halgren, 1996], keeping
the ligand and the protein residues flexible.
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4.3.2 Analysis of the model
Analysis of the global fold of the model
Expectedly, the same observations which were evident for the NK1 model (section
4.2.2) also apply for the global structure of the NK2 model: the global fold is similar
to that of the template structure (see Fig. 4.13). As no insertions or deletions occur in
the transmembrane regions, the Cα trace is completely identical. The geometry of the
loops, in particular of the β-hairpin, which interacts with NK2 antagonists, is unlikely
to correspond to the actual orientation in NK1 as the sequence identity between both
receptors is below 25 % in this sequence stretch.
Analysis of the modelled protein-ligand complexes
The binding at the NK2 receptor is not as extensively supported by mutational studies
in literature as binding to the NK1 receptor. Most binding (along with mutational)
data for antagonists are available for compound SR-48968 [Emonds-Alt et al., 1992].
According to the mutational data published in refs [Huang et al., 1995; Labrou et al.,
2001; Renzetti et al., 1999a,b; Bhogal et al., 1994; Giolitti et al., 2000; Donnelly et al.,
1999] the most essential residues for binding SR-48968 are His198, Tyr266, His267,
Phe270, Tyr289, Phe293, and Gln166. In particular, Tyr289 (TM VII), along with
Tyr266 and Phe270 (TM VI), are proposed to form part of the SR-48968 binding
pocket [Huang et al., 1995]. Giolitti et al. [Giolitti et al., 2000] propose as prime inter-
actions of SR-48968 the contacts to the aromatic ring of Tyr266 and both, the aromatic
ring and the OH group of Tyr289. According to their data, the binding site should
comprise Gln166 on TM IV, His198 on TM V, Tyr266 and Phe270 on TM VI for signif-
icant but not essential interactions, and Tyr289 as a crucial residue. Although binding
is not totally abrogated by the mutations Phe270Ala and Phe270Cys [Labrou et al.,
2001; Renzetti et al., 1999b; Huang et al., 1995; Giolitti et al., 2000], the decrease in
affinity is significant. Since the mutation Phe270Tyr [Labrou et al., 2001] results only in
minor affinity changes, the role of Phe270 could be (1) a hydrophobic interaction with
a corresponding part of the ligand, and (2) it stabilises the orientation of the neigh-
bouring aromatic residues Tyr266 and Tyr289 to perform favourable interactions with
the ligand. Furthermore, although not directly, Phe293 seems to play an important
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role in binding SR-48968. Interestingly, the single mutations Phe270Ala or Phe293Ala
do not affect SR-48968 binding but the double mutation Phe270Ala-Phe293Ala fully
abolishes SR-48968 binding. Similarly, with respect to SR-48968 binding, simultane-
ously mutating His267Phe and Phe293Ala produces an effect that was more than the
sum of those resulting from two point mutations. Surprisingly, in contrast to the NK1
receptor, Gln166 (Gln165 in the NK1 receptor, which performs an essential H-bond
in the NK1 receptor) does not seem to be crucially essential for binding, since the
mutation Gln166Val only slightly affects SR-48968 binding. In summary, in the NK2
receptor, the crucial interactions with the analysed ligands seem to be performed via
the hydrophobic patch defined by Tyr266, His267, Phe270, Tyr289, and Phe293.
Our model reproduces these observation. As shown in Fig. 4.14a, an H-bond is estab-
lished between the amide-O of SR-48968 and the Tyr266-OH (dashed lines). According
to our model, Tyr289-OH can also forms an H-bond with Tyr266-OH and possibly
stabilises its orientation and the interaction with the ligand. Although not exactly
observed in our model, it could well be that an H-bond network is established between
Tyr266, Tyr289, and the ligand (see Fig. 4.14a). This assumption is supported by
the fact that all NK2 antagonists show an H-bond acceptor at the corresponding po-
sition. Also the role of Phe270 and Phe293 can be explained by our model. Indeed,
no direct, specific interaction is observed for Phe293. Phe270, on the other hand, per-
forms a hydrophobic interaction with SR-48968. It furthermore seems to hold Tyr266
and, eventually, Tyr289 in position to interact with the ligand. As concluded from
the mutational data, Phe293 does not interact directly with the ligand, but it borders
the hydrophobic binding pocket and, similarly to Phe270, it seems to keep Tyr266 and
Tyr289 in position. According to our model, an H-bond with Gln166 is also possible,
however, as mentioned above, this interaction does not seem to be as essential for
binding as in the NK1 receptor (Fig. 4.14b).
Differences between the NK1 and NK2 receptor models
Fig. 4.15a displays those residues of the NK1 receptor, which are within 6.0 A˚ distance
to CP-96345 (residues coloured yellow) and the corresponding residues of the modelled
NK2 receptor (cyan). Fig. 4.15b depicts all those binding-site residues which are con-
served among NK1 and NK2 (in total 24 residues). Those residues which are mutated
among the NK1 and NK2 receptor are displayed in Fig. 4.15c. In the extracellular
region (residues at the top of the ligand), the degree of conservation seems to be lower
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Figure 4.14: Binding pockets of the (a) NK2 and (b) NK1 receptors and their
selective ligands SR-48968 (NK2) and CP-96345 (NK1)
than in the transmembrane region. Fig. 4.15d depicts all those residues which do not
belong to the extracellular region and are not conserved among the NK1 and NK2
receptor. From these (seven) residues, three (Lys194, Thr201, and Leu269 in the NK1
receptor) point away from the ligand, whereas Glu193 could possibly perform specific
interactions with antagonists (see also section 4.2). On the other hand, the residues
Phe264 and Met291, which are not conserved with respect to the NK2 receptor, are
part of the hydrophobic pocket depicted in Fig. 4.14. As discussed above, this part of
the binding pocket is essential for binding NK2 antagonists and could be relevant with
respect to selectivity between NK1 and NK2 antagonists.
Due to the low sequence identity of the β-hairpin region among the neurokinin receptors
and to rhodopsin, the homology models are probably too unprecise to allow for reliable
structural comparisons. It is very likely that this sequence stretch adopts distinct
conformations in the NK1 and NK2 receptor. This suggests that selectivity can be
modulated by addressing the corresponding region of the receptors.
Analysis of ligand data
Whereas CP-96345 binds selectively to the NK1 receptor, SR-48968 is selective for
the NK2 receptor (see Table 4.7, p. 100). ZD-6021 shows similar affinities to both
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receptors. Interestingly, ZD-6021 and SR-48968 are relatively similar, differing only in
the substitution of the piperidine ring and the phenyl ring of the benzamide group.
It was indeed shown that by modifying this phenyl ring the degree of NK1 and NK2
activity can be modulated (for example, refs [Shih et al., 2002; Burkholder et al., 1996;
Qi et al., 1998; Bernstein et al., 2001; Albert et al., 2002]). For example, as discussed for
the NK1 homology model (see section 4.1.3), 3,5-disubstitutions on the benzyl group,
especially by CF3 can markedly enhance the activity for the NK1 receptor. However,
these effect could not be rationalised quantitatively by the NK1 homology model.
Another option to modulate selectivity to the NK1 and NK2 receptor is the substitution
of the piperidine ring. According to the NK2 model, substituents at this ring interact
with the extracellular region of the receptor. As the model is probably not reflecting the
native structure in this region, insights into structure-activity relationships should not
be based on the model but on the analysis of ligand data, for example cf [Gerspacher
et al., 2001; Ting et al., 2000, 2001, 2002; Nishi et al., 1999; Qi et al., 1998; Mah et al.,
2002; Bernstein et al., 2001; Albert et al., 2002; Reichard et al., 2002].
4.3.3 Discussion
Computer-aided inhibitor design is concerned with the task of (1) finding and (2) op-
timising lead structures. In this thesis, it was shown for the NK1 receptor that the
derived homology model was sufficient for identifying a lead structure with submi-
cromolar affinity. However, trends in binding affinity for known inhibitors could not
be reproduced at a quantitative level. A possible approach for optimising our novel
NK1 lead structure, is to consider structure-activity relationships by analysis of known
potent NK1 antagonists (see 4.2.6).
Our approach of combining protein- and ligand-based information in a computer-aided
screening procedure should also be followed to discover novel dual antagonists for the
NK1 and NK2 receptor. Based on the insights of the NK2 homology model (in complex
with SR-48968) and on the analysis of ligand data, a 3D pharmacophore model could
be derived that is general enough to filter potential NK1 and NK2 antagonists. This
pharmacophore model would comprise the phenyl ring B of the NK1 model as given
in Figures 4.5 and 4.10 (p. 74 and 88). Furthermore, an H-bond acceptor is required.
The spatial tolerances should be defined large enough to enable an H-bond to Gln165
(for binding the NK1 receptor) and (simultaneously) to Tyr266 (for binding the NK2
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receptor, see Fig. 4.14). Finally, the pharmacophore should include the aromatic
moiety C (Fig. 4.5, p. 74).
Since sufficient data about ligand binding affinities are available for the NK1 and NK2
receptor, lead structure optimisation should be followed by analysing affinity data
about known ligands. This holds in particular for the modulation of NK1 and NK2
selectivity. In the case of the NK1 and NK2 receptors, this approach is probably an
attractive procedure since a vast number of information is available in the literature. As
inferred by analysis of the homology models and ligand data, NK1 and NK2 selectivity
can be modulated by variations in the region (1) pointing to the extracellular region
or (2) pointing to the hydrophobic subpocket of the receptors.
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Figure 4.15: Comparison of the NK1 and NK2 receptor models. The 24 antagonist
binding-site residues of the NK1 (yellow) and NK2 receptor (cyan) are shown (a). (b)
depicts all residues that are conserved among the NK1 and NK2 receptor (12 residues).
(c) shows the 12 residues that are mutated among the NK1 and NK2 receptor, (d)
depicts only those mutated residues that do not belong the extracellular region (7
residues). The residues of the NK1 receptor are labelled.
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5.1 Summary
Recent advances in the various genome sequencing projects have opened the floodgates
to thousands of protein sequences, possibly coding for new targets in drug discov-
ery. Thus increasingly, for a considerable part of putative drug targets, the three-
dimensional structure will not be readily available. In such cases, the most reliable
computer-based technique to generate a three-dimensional protein structure is homol-
ogy modelling. As homology modelling only considers information available from the
related protein structures, it has to remain on a rather approximate level if in the
target protein several amino acids of the active site are replaced with respect to those
in the template protein(s).
In this thesis, a novel strategy (MOBILE (Modelling Binding Sites Including Ligand
Information Explicitly)) was developed that models protein binding-sites simultane-
ously considering information about the binding mode of bioactive ligands during the
homology modelling process (chapter 3). As a result, protein binding-site models of
higher accuracy and relevance can be generated.
Starting with the (crystal) structure of one or more template proteins, in the first
step several preliminary homology models of the target protein are generated using the
homology modelling program MODELLER. Ligands are then placed into these pre-
liminary models using different strategies depending on the amount of experimental
information about the binding mode of the ligands. (1.) If a ligand is known to bind
to the target protein and the crystal structure of the protein-ligand complex with the
related template protein is available, it can be assumed that the ligand binding modes
are similar in the target and template protein. Accordingly, ligands are then trans-
ferred among these structures keeping their orientation as a restraint for the subsequent
modelling process. (2.) If no complex crystal structure with the template is available,
the ligand(s) can be placed into the template protein structure by docking, and the
resulting orientation can then be used to restrain the following protein modelling pro-
cess. Alternatively, (3.) in cases where knowledge about the binding mode cannot
be inferred by the template protein, ligand docking is performed into an ensemble of
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homology models. The ligands are placed into a crude binding-site representation via
docking into averaged property fields derived from knowledge-based potentials. Once
the ligands are placed, a new set of homology models is generated. However, in this
step, ligand information is considered as additional restraint in terms of the knowledge-
based DrugScore protein-ligand atom pair potentials. Consulting a large ensemble of
produced models exhibiting different side-chain rotamers for the binding-site residues,
a composite picture is assembled considering the individually best scored rotamers with
respect to the ligand. After a local force-field optimisation, the obtained binding-site
models can be used for structure-based drug design.
The incorporation of the knowledge-based DrugScore pair-potentials as additional re-
straints into the MODELLER force-field was adjusted using a test data set of 46
protein-ligand complexes extracted from the Protein Data Bank (PDB). The use of
the DrugScore pair potentials proved not only efficient to restrain the homology mod-
elling process, they were also successfully applied to score and optimise the modelled
complexes (section 3.2.1). For 70 % of the complexes in the test set, near-native
binding-site geometries were produced (root-mean-square deviation (rmsd) ≤ 2.0 A˚)
with MODELLER considering a bound ligand in its native orientation. Scoring the
resulting complexes with DrugScore revealed, in 66 % of the cases a near-native binding
mode (rmsd ≤ 2.0 A˚) on rank 1.
MOBILE has been applied to two case studies (sections 3.2.2 and 3.2.2). In the first ex-
ample, factor Xa was modelled based on the crystal structure of trypsin. After docking
the ligand RPR128515 flexibly into preliminary factor Xa models, new homology mod-
els were generated with the MOBILE approach including the ligand in its orientation
crystallised with trypsin. To validate the correctness of the model, 10 known factor Xa
inhibitors were docked into the factor Xa model and, for reasons of comparison, into a
crystallographically determined factor Xa structure. Since similar docking poses and
energy scores were obtained for all considered ligands, the generated model appears to
be well suited for structure-based drug design purposes.
In another example, different sets of models of aldose reductase were generated based on
the crystal structure of aldehyde reductase and (1) the ligand tolrestat or (2) IDD594,
which are known to induce conformational changes in the protein affecting even the
backbone. This study demonstrated that relevant protein-ligand geometries can even
be generated by MOBILE in case of a rather complex system, where the bound ligands
reinforce different loop conformations upon binding. Furthermore, it was shown that
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the mutual orientations between the protein and a particular ligand can be adjusted in
a stepwise fashion. Even though the initial starting protein-ligand geometries deviated
considerably from the orientations found in the corresponding crystal structures, near-
native geometries could be generated for different complexes after performing a second
cycle with the MOBILE approach.
As a real-life test scenario we applied MOBILE to the neurokinin-1 (NK1) receptor, a
member of the superfamily of G-Protein coupled receptors (GPCRs) which mediate re-
sponses to, e.g. visual, olfactory, hormonal, or neurotransmitter signals (4). This class
represents one of the most relevant target families for small-molecule drug design. Due
to the fact that GPCRs are membrane-bound proteins, their expression, purification,
crystallisation and structure determination remain a major enterprise. So far, only the
structure of bovine rhodopsin could be determined to sufficiently high resolution. The
NK1 receptor belongs to the series of tachykinin-binding receptors (NK1, NK2, and
NK3). They selectively bind the peptide neurotransmitters substance P, neurokinin
A, and neurokinin B, respectively. Substance P plays a role in the transmission of
pain and is involved in inflammation and immune response. The probably best studied
NK1 antagonist is CP-96345. Considerations about its bioactive conformation were
achieved through several theoretical and experimental studies. Through mutational
studies and comparative affinity determinations based on CP-96345 binding, the es-
sential amino acids involved in ligand recognition could be identified and translated
into a crude topographical interaction model (Fig. 4.5, p. 74). The sequence identity
between bovine rhodopsin and the NK1 receptor amounts to 21 %. Considering only
the transmembrane regions, this figure increases to 27 %. However, regarding only the
antagonist binding site of the NK1 receptor, no sequence identity can be detected.
In the first step, 100 preliminary homology models based on the crystal structure
of rhodopsin were generated. Next, CP-96345 was docked rigidly into the modelled
binding pockets with AutoDock, using the conformation observed in its small-molecule
crystal structure (CSD Refcode: LEWCUL). From the set of docked ligand poses,
we selected that solution which satisfied the key interactions of our topographical
model best. Subsequently, new homology models were generated explicitly considering
bound CP-96345. The best-scored side-chain orientations of the individual models were
merged in a combinatorial fashion. Finally, the model was selected that yielded the
best total DrugScore value avoiding any unfavourable intramolecular contacts among
individual amino acid side-chains. The binding-site of the finally composed complex
(Fig. 4.9, p. 85) reproduced convincingly well the proposed interactions observed in the
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topographical model. The relevance of the model was validated by probing its ability
to accommodate other known NK1 antagonists from structurally diverse compound
classes.
Mutational data and features shared in common by known NK1 antagonists were then
used to establish a pharmacophore hypothesis to retrieve candidate ligands from seven
databases containing in total about 800000 compounds. A hierarchical search strategy
consisting of 2D and 3D filters of increasing complexity was applied using the programs
Selector and UNITY. The 11109 compounds remaining after these filtering steps were
flexibly docked into the modelled NK1 binding pocket using the program FlexX-Pharm
and scored with DrugScore. After minimising the produced complexes of the best-
ranked solutions using MOLOC, the best hits were inspected visually analysing their
adopted binding modes, the agreement with the proposed topographical interaction
model, and the mutual surface complementarity between protein and accommodated
ligand. Finally, seven compounds were selected for biochemical testing. Out of these,
one (29) showed at 251 nM binding affinity. Considering that CP-96345 and 29 are
similar with respect to their pharmacophore features (Fig. 4.11, p.94), but distinct
with respect to their molecular skeletons, suggests that this hit would not be matched
as one of the top hits using a solely ligand-based or solely protein-based screening
approach.
A further step towards homology modelling GPCRs for structure-based drug design
was undertaken by generating a ligand-supported homology model of the neurokinin-2
(NK2) receptor (section 4.3). Both, NK1 and NK2 receptors appear to be involved
in pulmonary pathophysiology. Accordingly, agents that simultaneously antagonise
NK1 and NK2 may have therapeutic applications. Following the MOBILE approach,
ligand-supported NK2 models were generated that were restrained by the NK2-selective
antagonist SR-48968. The modelled antagonist binding pockets of the NK1 and NK2
receptors, showing an overall sequence identity of 75 %, were compared and the fea-
tures responsible for binding the NK1-selective antagonist CP-96345, the NK2-selective
antagonist SR-48968, and the dual antagonist ZD-6021 were rationalised on the basis
of the homology models. These insights, together with the generated models, might be
a useful platform for the design of further ligands antagonising NK1 and NK2.
In summary we can conclude that our ligand-supported homology modelling produces
binding-site models that can be successfully applied as platform for structure-based
drug design. The fact that the post-genomic era will provide us with about a factor
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of ten more new drug targets of unknown structure, emphasises the relevance and
demand for such method. This is in particular the case for the family of the GPCRs
where structure determination will probably remain a major enterprise in the next
future. Consequently, the successful application of the MOBILE procedure to the NK1
receptor opens a perspective field for the discovery of novel antagonists for a large
subset of members of the GPCR family.
5.2 Zusammenfassung
Durch die Fortschritte in den Genomsequenzierungsprojekten werden in na¨chster Zeit
tausende von Proteinsequenzen entschlu¨sselt werden, die fu¨r neue Zielproteine (”Tar-
gets”) fu¨r die Arzneimittelforschung kodieren. Fu¨r einen betra¨chtlichen Anteil dieser
neuen Targets wird die dreidimensionale Struktur nicht unmittelbar zur Verfu¨gung
stehen. Die Homologiemodellierung ist die zuverla¨ssigste computergestu¨tzte Methode,
um die dreidimensionale Struktur eines Proteins vorherzusagen. Voraussetzung fu¨r
die Anwendung dieser Methode ist das Vorhandensein einer experimentell aufgekla¨rten
Templat-Proteinstruktur mit ausreichend hoher Sequenzidentita¨t zum Zielprotein. Sie
verbleibt bis zu einem gewissen Grad ungenau, insbesondere dann, wenn sich Templat-
und Zielprotein in ihrer Sequenz im aktiven Zentrum unterscheiden.
In dieser Arbeit wurde eine neue Methode (MOBILE (Modelling Binding Sites Including
Ligand Information Explicitly)) entwickelt, die Modelle von Proteinbindetaschen er-
stellt (Kapitel 3). Durch die explizite Mitberu¨cksichtigung von Liganden wa¨hrend
der Homologiemodellierung gelingt es, Bindetaschenmodelle ho¨herer Genauigkeit und
Relevanz zu erstellen.
Ausgehend von der Kristallstruktur eines oder mehrerer Templatproteine werden
zuna¨chst vorla¨ufige Homologiemodelle des Zielproteins erstellt. Im na¨chsten Schritt
werden bioaktive Liganden in diese vorla¨ufigen Modelle eingepaßt. Dabei werden,
je nach vorhandenem Informationsgehalt u¨ber die Ligandenbindung, unterschiedliche
Strategien verfolgt. (1.) Gibt es einen Liganden, der an Ziel- und Templatprotein
bindet und ist daru¨ber hinaus die Kristallstruktur des Protein-Ligand Komplexes mit
dem Templatprotein vorhanden, wird der Ligand zwischen diesen Strukturen trans-
feriert und in dieser Orientierung als Randbedingung fu¨r die folgende Homologiemod-
ellierung vorgegeben. (2.) Wenn keine Kristallstruktur des Templatproteins mit dem
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Liganden gegeben ist, wird der Ligand durch Docking in das Templatprotein plaziert
und in der resultierenden Orientierung als Randbedingung fu¨r die folgende Protein-
modellierung verwendet. (3.) Ko¨nnen Erkenntnisse u¨ber die Ligandenbindung nicht
u¨ber das Templatprotein gewonnen werden, wird der Ligand in angena¨herte Binde-
taschenrepra¨sentationen des modellierten Zielproteins eingepaßt. Diese Bindetaschen-
repra¨sentationen werden durch sogenannte gemittelte Eigenschaftsfelder beschrieben,
die durch wissensbasierte Potentiale abgeleitet werden. Basierend auf der erhaltenen
Ligandenorientierung werden im na¨chsten Schritt mehrere neue Homologiemodelle
erstellt. Dabei wird der Ligand als zusa¨tzliche Randbedingung in Form der wissens-
basierten DrugScore Protein-Ligand Atom-Paarpotentiale beru¨cksichtigt. Bei dem
resultierenden Ensemble der generierten Homologiemodelle weisen die Aminosa¨uren
im aktiven Zentrum unterschiedliche Seitenkettenkonformationen auf. Daraus wird
ein optimiertes Modell zusammengesetzt, indem zuna¨chst die individuellen Rotamere
bezu¨glich ihrer Wechselwirkung zum Liganden bewertet und anschließend so miteinan-
der kombiniert werden, daß die Gesamtbewertung der zusammengesetzten Bindetasche
maximal ist. Nach einer lokalen Kraftfeldminimierung ko¨nnen die resultierenden Binde-
taschenmodelle fu¨r strukturbasiertes Wirkstoffdesign verwendet werden.
Die Einbindung der wissensbasierten DrugScore Paarpotentiale als zusa¨tzliche Randbe-
dingung in das MODELLER Kraftfeld erfolgte durch eine Parameterisierung an einem
Datensatz von 46 Protein-Ligand Komplexen aus der Proteindatenbank (PDB). Die
Verwendung der DrugScore Potentiale erwies sich nicht nur als geeignet fu¨r die Gener-
ierung von Homologiemodellen, sie wurden auch erfolgreich zur Bewertung und Opti-
mierung der modellierten Protein-Ligand Komplexe eingesetzt (Abschnitt 3.2.1). Fu¨r
den Testdatensatz wurden in 70 % der Fa¨lle nativ-a¨hnliche Bindetaschenmodelle (rmsd
≤ 2.0 A˚) erstellt, wenn der Ligand in seiner Orientierung aus der Kristallstruktur als
zusa¨tzliche Randbedingung in die Homologiemodellierung einbezogen wurde. Bei der
Bewertung dieser Modelle mit den DrugScore Paarpotentialen wurden in 66 % der
Fa¨lle Orientierungen mit einer mittleren quadratischen Abweichung ≤ 2.0 A˚ auf Rang
1 gefunden.
MOBILE wurde fu¨r zwei Teststudien verwendet (Abschnitte 3.2.2 and 3.2.2). Im er-
sten Fall wurde die Struktur von Faktor Xa basierend auf der Kristallstruktur von
Trypsin modelliert. Nachdem der Ligand RPR128515 flexibel in vorla¨ufige Faktor Xa
Modelle eingepaßt wurde, wurden neue Homologiemodelle erstellt. Dabei wurde der
Ligand explizit in seiner Orientierung aus der Trypsinkristallstruktur miteinbezogen.
Um die Relevanz des Modells zu validieren, wurden 10 weitere bekannte Inhibitoren in
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das Faktor Xa Model eingepaßt. Aus Vergleichsgru¨nden wurden dieselben Verbindun-
gen zusa¨tzlich in eine Faktor Xa Kristallstruktur plaziert. Fu¨r alle Liganden wurden
a¨hnliche Lo¨sungen sowohl hinsichtlich ihrer Orientierung als auch hinsichtlich ihrer En-
ergiewerte erhalten. Folglich scheint das Model fu¨r strukturbasiertes Wirkstoffdesign
gut geeignet zu sein.
In der zweiten Studie wurden zwei unterschiedliche Serien von Aldose Reduktase Ho-
mologiemodellen erstellt. Die Liganden (1) Tolrestat bzw. (2) IDD594, die konforma-
tionelle A¨nderungen im Protein hervorrufen, wurden jeweils in die Homologiemodel-
lierung einbezogen. Dieses Beispiel demonstrierte, daß MOBILE auch dann erfolgre-
ich realistische Protein-Ligand Geometrien generiert, wenn zwei Liganden durch ihre
Bindung unterschiedliche Konformationen der Loop-Regionen induzieren. Daru¨ber hin-
aus wurde gezeigt, daß die Orientierungen zwischen dem Protein und einem spezifischen
Liganden in einem schrittweisen Verfahren aneinander angepasst werden ko¨nnen. Ob-
wohl die Startgeometrien zwischen Protein und Ligand betra¨chtlich von der jeweiligen
Kristallstruktur abwichen, wurden nach Durchfu¨hrung eines zweiten MOBILE Zyklus
nativ-a¨hnliche Komplexgeometrien erhalten.
Im Rahmen eines realen Modellierungsproblems wurdeMOBILE fu¨r die Erstellung von
Homologiemodellen fu¨r den Neurokinin-1 (NK1) Rezeptor verwendet. Dieser Rezeptor
geho¨rt zur Familie der G-Protein gekoppelten Rezeptoren (GPCRs), die Reaktionen auf
verschiedenste Signale (z.B. optische, geruchliche, hormonelle oder neurotransmitter-
vermittelte) u¨bermitteln. Die Klasse der GPCRs ist eine der relevantesten Zielfamilien
des aktuellen Wirkstoffdesigns. Da GPCRs membran-gebundene Proteine sind, ist ihre
Expression, Aufreinigung, Kristallisation und Strukturaufkla¨rung immer noch nicht
gelo¨st. Bisher konnte nur die Kristallstruktur von Rinderrhodopsin in genu¨gend hoher
Auflo¨sung bestimmt werden. Der NK1 Rezeptor geho¨rt zu den Tachykinin binden-
den Rezeptoren (NK1, NK2 und NK3), die selektiv an die peptidischen Neurotrans-
mitter Substanz P, Neurokinin A und Neurokinin B binden. Substanz P spielt eine
wichtige Rolle in der Schmerzu¨bertragung und ist an Entzu¨ndungsprozessen und Im-
munantworten beteiligt. Der wahrscheinlich am besten untersuchte NK1 Antagonist
ist CP-96345. Erkenntnisse u¨ber dessen bioaktive Konformation wurden durch eine
Reihe von theoretischen und experimentellen Untersuchungen gewonnen. Durch Mu-
tationsstudien und vergleichende Affinita¨tsbestimmungen, basierend auf der Bindung
von CP-96345, konnten die essentiell an der Ligandenbindung beteiligten Aminosa¨uren
identifiziert und in ein topographisches Wechselwirkungsmodell u¨bersetzt werden (Fig.
4.5, S. 74). Die Sequenzidentita¨t zwischen Rinderrhodopsin und dem NK1 Rezep-
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tor betra¨gt 21 %. Betrachtet man nur die Transmembranregion, steigt sie auf 27 %.
Werden jedoch nur die Aminosa¨uren der Antagonistenbindungsstelle beru¨cksichtigt, so
beobachtet man u¨berhaupt keine Sequenzidentita¨t.
Basierend auf der Kristallstruktur von Rinderrhodopsin wurden zuna¨chst 100 vorla¨ufige
Homologiemodelle erstellt. Im na¨chsten Schritt wurde CP-96345 mit AutoDock in die
modellierten Bindetaschen plaziert. Dabei wurde der Ligand rigide in seiner Orien-
tierung aus der Kristallstruktur (CSD Referenzcode: LEWCUL) eingesetzt. Die am
besten bewerteten Aminosa¨uren der individuellen Proteinmodelle wurden kombina-
torisch zusammengesetzt und das Modell mit der besten gesamten DrugScorebewer-
tung ausgewa¨hlt. Die im topographischen Modell (Fig. 4.9, S. 85) vorgeschlagenen
Wechselwirkungen werden durch das resultierende Modell gut reproduziert. Die Rel-
evanz dieses NK1 Modells wurde durch die Vorhersage der Bindungsmodi weiterer
bekannter NK1 Antagonisten aus strukturell verschiedenen Klassen besta¨tigt. Mu-
tationsdaten und gemeinsame strukturelle Eigenschaften bekannter NK1 Antagonis-
ten wurden anschließend in eine Pharmakophor-Hypothese umgesetzt. Basierend auf
dieser Pharmakophor-Hypothese wurden in einer Datenbanksuche Liganden aus sieben
Datenbanken mit insgesamt 800000 Verbindungen durchmustert. Dieses virtuelle
Screening wurde schrittweise mit den Programmen Selector und UNITY durchgefu¨hrt.
Es bestand aus mehreren hierarchischen 2D und 3D Filterschritten mit zunehmender
Komplexita¨t. Die erhaltenen 11109 Verbindungen wurden anschließend mit dem Pro-
gramm FlexX-Pharm in die modellierte NK1 Bindetasche plaziert und mit DrugScore
bewertet. Nach einer lokalen Kraftfeldminimierung der resultierenden Komplexe mit
MOLOC wurden die besten Treffer einer visuellen Inspektion unterzogen. Dabei wur-
den die Bindungsmodi insbesondere hinsichtlich ihrer U¨bereinstimmung mit dem to-
pographischenWechselwirkungsmodell und hinsichtlich ihrer Oberfla¨chenkomplementarita¨t
zwischen Protein und Ligand beurteilt. Sieben Verbindungen wurden fu¨r eine bio-
chemische Testung ausgewa¨hlt. Von diesen zeigte eine (29) eine Bindungsaffinita¨t von
251 nM. CP-96345 und 29 a¨hneln sich bezu¨glich ihrer Pharmakophoreigenschaften
(Fig. 4.11, p.94), sie weisen aber unterschiedliche molekulare Geru¨ste auf. Folglich
wa¨re dieser Ligand vermutlich nicht als als einer der besten Treffer in einem rein
protein- oder rein ligand-basierten Screening gefunden worden.
Ein weiterer Schritt in Richtung ”Homologiemodellierung von GPCRs fu¨r struktur-
basiertes Wirkstoffdesign” wurde durch die Erstellung eines liganden-verfeinerten Ho-
mologiemodells fu¨r den Neurokinin-2 (NK2) Rezeptors unternommen. Sowohl der
NK1 als auch der NK2 Rezeptor sind offenbar in Lungenerkrankungen involviert. De-
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mentsprechend ko¨nnten Substanzen, die gleichzeitig NK1 und NK2 antagonisieren,
therapeutische Anwendung finden. Mit MOBILE wurden unter Beru¨cksichtigung des
NK2-selektiven Antagonisten SR-48968 ligandengestu¨tzte Homologiemodelle des NK2
Rezeptors erstellt. Die modellierten Bindetaschen des NK1 und NK2 Rezeptors, die
eine Sequenzidentita¨t von 75 % aufweisen, wurden hinsichtlich ihrer Bindung zu dem
NK1-selektiven Antagonisten CP-96345, dem NK2-selektiven Antagonisten SR-48968
und dem dualen Antagonisten ZD-6021 verglichen. Die gewonnenen Erkenntnisse
ko¨nnen, zusammen mit den generierten Homologiemodellen, als nu¨tzliche Grundlage
fu¨r die Entwicklung weiterer NK1 und NK2 Antagonisten dienen.
Zusammenfassend kann festgestellt werden, daß durch liganden-unterstu¨tzte Ho-
mologiemodellierung Proteinbindetaschenmodelle generiert werden, die erfolgreich als
Grundlage fu¨r strukturbasiertes Wirkstoffdesign verwendet werden ko¨nnen. Die Tat-
sache, daß die Genomprojekte uns mit zahlreichen neuen Arzneistofftargets versorgen
wird, verdeutlicht die Relevanz und Notwendigkeit einer solchen Methode. Dies gilt
insbesondere fu¨r die Familie der GPCRs, die fu¨r die experimentelle Strukturbestim-
mung voraussichtlich auch in der Zukunft eine bedeutende Hu¨rde darstellen wird. Die
erfolgreiche Anwendung der MOBILE Methode fu¨r den NK1 Rezeptor ero¨ffnet eine
neue Perspektive fu¨r die Entdeckung von Antagonisten auch fu¨r andere Mitglieder der
GPCR Familie.
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